Myeloproliferative neoplasm
MONDO:0020076A clonal hematopoietic stem cell disorder, characterized by proliferation in the bone marrow of one or more of the myeloid (i.e., granulocytic, erythroid, megakaryocytic, and mast cell) lineages. It is primarily a neoplasm of adults. (WHO 2008)
Also known as: CMPD, MPD, MPN, chronic myeloproliferative disease, chronic myeloproliferative disorder, chronic myeloproliferative neoplasm, myeloproliferative disorder, myeloproliferative neoplasm
4415 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsSub-types
Broader categories
Showing the 400 most recently updated of 913 trials in this tab.
-
Can specially trained immune cells flush out hidden HIV?
⭐️ CURE ⭐️ OngoingThis early-stage trial is testing whether immune cells from a donor, specially trained to attack HIV, can safely reduce the hidden HIV reservoir in people who have had a bone marrow transplant. Participants are adults with HIV who are on antiretroviral therapy and have already re…
Phase: PHASE1 • Sponsor: Catherine Bollard • Aim: ⭐️ CURE ⭐️
Last updated Aug 16, 2026 00:00 UTC
-
Can engineered immune cells outsmart Hard-to-Treat blood cancers?
⭐️ CURE ⭐️ OngoingThis early-stage trial is testing an experimental cell therapy for people with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) that has returned or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to recognize …
Phase: PHASE1 • Sponsor: Arcellx, Inc. • Aim: ⭐️ CURE ⭐️
Last updated Aug 13, 2026 00:00 UTC
-
Can a gentler chemo-radiation combo make stem cell transplants safer for blood cancers?
⭐️ CURE ⭐️ OngoingThis trial tests a new, lower-intensity combination of chemotherapy and radiation before a donor stem cell transplant for people with high-risk blood cancers or aplastic anemia. The goal is to see if this approach is safe enough to allow the donor cells to take hold and cure the …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: ⭐️ CURE ⭐️
Last updated Jul 26, 2026 00:00 UTC
-
New vaccine aims to shield transplant patients from deadly virus
⭐️ VACCINE ⭐️ OngoingThis phase II trial tests a vaccine designed to protect stem cell transplant recipients from cytomegalovirus (CMV), a common virus that can cause serious illness in people with weakened immune systems. The vaccine uses a modified, harmless virus to deliver three CMV proteins, tra…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jul 30, 2026 00:00 UTC
-
New vaccine aims to better protect blood cancer patients from COVID-19
⭐️ VACCINE ⭐️ OngoingThis study tests a new COVID-19 vaccine (GEO-CM04S1) in 63 adults with blood cancers like leukemia or lymphoma who have had a stem cell transplant or cell therapy. The goal is to see if this vaccine triggers a stronger immune response than standard mRNA vaccines, potentially offe…
Phase: PHASE2 • Sponsor: GeoVax, Inc. • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:04 UTC
-
Cancer vaccine aims to prevent leukemia relapse in older adults
⭐️ VACCINE ⭐️ OngoingThis study tests a personalized vaccine made from a patient's own leukemia cells and immune cells. The goal is to see if the vaccine can help prevent the cancer from coming back after chemotherapy. It is for adults aged 55 and older with acute myeloid leukemia (AML) who are in re…
Phase: PHASE2 • Sponsor: Beth Israel Deaconess Medical Center • Aim: ⭐️ VACCINE ⭐️
Last updated Jun 27, 2026 09:01 UTC
-
New combo therapy targets high-risk MDS in early trial
Disease control TerminatedThis study tests a new two-drug combination (pacritinib plus azacitidine) for people with moderate to very high risk myelodysplastic syndrome (MDS), a bone marrow disorder. The first part finds the safest dose of pacritinib, and the second part checks how well the combination wor…
Phase: PHASE1, PHASE2 • Sponsor: Thomas Jefferson University • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Could cutting vitamin B6 boost cancer immunotherapy?
Disease control OngoingThis early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …
Phase: PHASE1 • Sponsor: West China Hospital • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Experimental drug combo targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing whether combining two drugs—erlotinib and irinotecan—can safely treat advanced solid tumors that have not responded to standard care. Erlotinib blocks signals that help cancer cells grow, while irinotecan is a chemotherapy drug that stops cancer …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Lower drug dose after transplant may cut infections without losing protection
Disease control OngoingThis study tests whether a lower dose of the drug cyclophosphamide, given after a stem cell transplant from a partially matched donor, can reduce serious infections in the first 100 days while still preventing graft-versus-host disease (a common complication where donor cells att…
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Aug 18, 2026 03:00 UTC
-
Cancer drug targets genetic weakness in advanced tumors
Disease control OngoingThis phase 2 study tests the drug olaparib in 329 people with advanced solid tumors that have certain DNA repair mutations (HRRm) or deficiencies (HRD). Participants have already tried standard treatments without success. The main goal is to see if olaparib can shrink tumors, wit…
Phase: PHASE2 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New stem cell therapy aims to tame transplant complications
Disease control OngoingThis study tests a new treatment called Orca-T for people with advanced blood cancers like leukemia. It uses a special mix of stem cells and immune cells from a donor to help the body accept the transplant while reducing serious side effects like graft-versus-host disease. The go…
Phase: PHASE1 • Sponsor: Orca Biosystems, Inc. • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
Special blood storage could cut transfusions for cancer patients
Disease control OngoingThis study tests whether red blood cells stored with less oxygen (hypoxic RBCs) are safer and more effective than standard transfusions for people with blood cancers who need regular blood. About 24 adults with transfusion-dependent blood cancers will receive both types of blood …
Phase: NA • Sponsor: Hemanext • Aim: Disease control
Last updated Aug 16, 2026 00:00 UTC
-
New hope for blood disorder patients: experimental drug bomedemstat enters final trial phase
Disease control OngoingThis study tests a new drug called bomedemstat against the best available treatments for people with essential thrombocythemia (a blood disorder causing too many platelets) who did not respond well to or couldn't tolerate the standard drug hydroxyurea. About 340 adults will be ra…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a targeted drug outperform standard care for rare blood cancers?
Disease control OngoingThis trial compares the drug ruxolitinib against the best available standard treatments for people with high-risk polycythemia vera (PV) or essential thrombocythemia (ET), two rare blood cancers that cause overproduction of blood cells and can lead to clots, bleeding, and severe …
Phase: PHASE2 • Sponsor: RWTH Aachen University • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a modified interferon rein in early myelofibrosis?
Disease control OngoingThis phase 3 trial is testing whether ropeginterferon alfa-2b, a biologic drug, can help control blood cell counts and symptoms in adults with early or low-risk primary myelofibrosis, a bone marrow disorder. Participants receive either the drug or a placebo every two weeks for up…
Phase: PHASE3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a Dual-Action pill tame bone marrow tumors?
Disease control TerminatedThis phase 1 trial is testing an experimental pill called flonoltinib maleate in people with certain bone marrow tumors, including myelofibrosis, polycythemia vera, and essential thrombocythemia. The drug targets two proteins involved in abnormal blood cell growth. The study aims…
Phase: PHASE1 • Sponsor: Guizhou Bailing Group Pharmaceutical Co Ltd • Aim: Disease control
Last updated Aug 15, 2026 00:00 UTC
-
Can a new pill shrink the spleen in myelofibrosis?
Disease control OngoingThis trial is testing an experimental drug called flonoltinib in people with intermediate to high-risk myelofibrosis, a type of bone marrow cancer that often causes an enlarged spleen. Participants will be randomly assigned to receive either a low or high dose of flonoltinib, or …
Phase: PHASE2 • Sponsor: Chengdu Zenitar Biomedical Technology Co., Ltd • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New cancer drug CHS-114 enters first human tests
Disease control OngoingThis early-stage trial tests a new drug called CHS-114, alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the right dose, and see how the body handles th…
Phase: PHASE1 • Sponsor: Coherus Oncology, Inc. • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
New hope for rare blood cancers? early trial begins
Disease control OngoingThis early-phase study tests a new drug called INCB160058 in adults with myeloproliferative neoplasms, a group of rare blood cancers. The main goal is to check the drug's safety and how the body processes it. About 186 participants will receive the drug to find the right dose and…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 14, 2026 00:00 UTC
-
Cancer drug pertuzumab tested for Long-Term use in extension trial
Disease control OngoingThis study gives continued access to the cancer drug pertuzumab (Perjeta) for people with solid tumors who were already benefiting from it in a previous Roche trial. About 154 participants will receive the drug every 3 weeks, alone or with other treatments, until their disease wo…
Phase: PHASE3 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: drug targets DNA repair weakness
Disease control OngoingThis phase 2 trial is testing the drug talazoparib in people with advanced solid tumors that have specific mutations in DNA repair genes. Talazoparib works by blocking a protein called PARP, which cancer cells use to fix their damaged DNA, leading to cancer cell death. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Precision drug shows promise for rare Gene-Driven cancers
Disease control OngoingThis study tests a drug called larotrectinib in 35 adults with advanced cancers (including lymphoma and solid tumors) that have a specific NTRK gene fusion. The drug blocks a faulty protein that tells cancer cells to grow, aiming to shrink tumors or stop them from spreading. Part…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New antibody takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…
Phase: PHASE1, PHASE2 • Sponsor: ImCheck Therapeutics, an Ipsen company • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Experimental cancer combo targets Hard-to-Treat tumours
Disease control OngoingThis early-stage trial tests a combination of two drugs—ceralasertib (a targeted therapy) and durvalumab (an immunotherapy)—in 14 Chinese patients with advanced solid tumours that have not responded to prior treatments. The main goal is to check safety and find the right dose. Re…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a pill shrink advanced tumors? a new drug steps into the spotlight
Disease control OngoingThis early-stage trial is testing an experimental pill called SIM0532 in adults with advanced solid tumors that have not responded to standard treatments. The study is split into two parts: first, to find a safe dose, and then to see if the drug can shrink tumors or slow their gr…
Phase: PHASE1 • Sponsor: Jiangsu Simcere Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Cancer patients who respond to drug get continued access in new study
Disease control ENROLLING_BY_INVITATIONThis study offers ongoing treatment with the cancer drug durvalumab to people who have already completed a previous study and are still benefiting from the drug, as decided by their doctor. The main goal is to monitor safety and side effects. About 214 participants will be enroll…
Phase: PHASE3 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New cancer drug SG2918 enters first human tests
Disease control OngoingThis early-stage trial tests an experimental drug called SG2918 in 17 people with advanced cancers that no longer respond to standard treatments. The main goal is to check safety and find the right dose, not yet to prove it works. Participants receive the drug by IV every three w…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug SG301 tested in blood cancer patients who have run out of options
Disease control OngoingThis early-stage trial is testing a new drug called SG301 in about 61 people with blood cancers like multiple myeloma that have returned or not responded to standard treatments. The main goal is to check the drug's safety and find the best dose to use in future studies. Researche…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Can a smart drug home in on Hard-to-Treat cancers?
Disease control OngoingThis trial is testing an experimental drug called XNW27011 in people with advanced solid tumors, such as pancreatic, lung, ovarian, colorectal, biliary tract, stomach, or gastroesophageal junction cancer, that have not responded to or are not eligible for standard treatments. XNW…
Phase: PHASE1, PHASE2 • Sponsor: Astellas Pharma Global Development, Inc. • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New drug combo aims to tame rare blood cancers
Disease control OngoingThis early-stage trial is testing a new drug called INCA033989, alone or with an existing drug ruxolitinib, in 225 people with myeloproliferative neoplasms (a group of blood cancers). The main goal is to check safety and find the best dose. Participants must have a specific genet…
Phase: PHASE1 • Sponsor: Incyte Corporation • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Promising combo targets tough leukemia
Disease control OngoingThis study tests a new way to treat adults with a specific type of leukemia (Ph+ ALL) that has come back or not responded to treatment. The approach combines low-intensity chemotherapy with two targeted drugs, ponatinib and blinatumomab, to kill cancer cells and boost the immune …
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a Gene-Targeted pill turn the tide against a rare blood cancer?
Disease control OngoingThis trial is testing an oral drug called AG-120 (ivosidenib) in adults with myelodysplastic syndrome (MDS) or a related early form of leukemia that carries a specific IDH1 gene mutation. The drug is designed to block the mutated enzyme that drives abnormal blood cell growth. Res…
Phase: PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug aims to stop leukemia from coming back after transplant
Disease control TerminatedThis early-phase trial tests a drug called DR-18 in 40 adults with acute myeloid leukemia or myelodysplastic syndrome whose cancer returned or persisted after a stem cell transplant. DR-18 is a modified immune protein designed to boost the body's natural defenses against cancer c…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a targeted pill turn the tide against a bone marrow disorder?
Disease control OngoingThis trial is testing an oral drug called enasidenib (AG-221) in people with myelodysplastic syndrome (MDS) who have a specific genetic change called an IDH2 mutation. The drug is designed to block the mutated enzyme and help restore normal blood cell production. Participants rec…
Phase: PHASE2 • Sponsor: Groupe Francophone des Myelodysplasies • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat leukemia
Disease control OngoingThis early-phase trial tests two oral drugs, olutasidenib and ziftomenib, together in 20 adults with a specific form of acute myeloid leukemia (AML) that has returned or not responded to treatment. The first part finds a safe dose; the second checks if that dose helps control the…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 12, 2026 00:00 UTC
-
Can a new drug shrink Hard-to-Treat tumors?
Disease control OngoingThis early-stage trial is testing an experimental drug called JS107 in people with advanced or metastatic solid tumors that have not responded to standard treatments. The study aims to find the safest dose and see how well the body tolerates JS107 when given alone or combined wit…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New cancer drug combo targets Hard-to-Treat tumors
Disease control TerminatedThis early-phase study tests a new drug, BI 1831169, given alone or with an immunotherapy (anti-PD-1 antibody) in adults with advanced solid tumors that cannot be removed by surgery or have spread. The main goals are to find the highest safe dose and see if the treatment shrinks …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo shows promise for MDS and AML
Disease control OngoingThis study tests two drugs, vorinostat and azacitidine, together in people with myelodysplastic syndrome (MDS) or acute myeloid leukemia (AML). The goal is to find the best dose and see if the combination is safe and effective. About 135 participants will take part in this early-…
Phase: PHASE1, PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 09, 2026 00:00 UTC
-
New drug combo targets tough cancers in early trial
Disease control OngoingThis early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …
Phase: PHASE1 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New transplant recipe may tame Graft-Versus-Host disease in blood cancer patients
Disease control OngoingThis study tests a specific timing of chemotherapy drugs (busulfan and fludarabine) before a donor stem cell transplant, followed by cyclophosphamide after the transplant, to treat high-risk blood cancers like leukemia and lymphoma. The goal is to reduce the chance of the transpl…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New strategy cuts early deaths in rare leukemia
Disease control OngoingThis study tested a simplified care plan for people with acute promyelocytic leukemia (APL), a rare blood cancer. The goal was to see if following easy-to-use guidelines and getting support from APL experts could lower the number of deaths soon after starting treatment. About 200…
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Cancer drug olaparib gets a makeover: which pill works best?
Disease control OngoingThis phase I trial tests two different oral forms of the cancer drug olaparib (AZD2281) in people with advanced solid tumors that have not responded to standard treatments. The main goal is to see how well the body absorbs each form. About 197 participants will receive both forms…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New hope for older leukemia patients: targeted combo shows promise
Disease control OngoingThis study is for adults with a specific type of acute myeloid leukemia (CD123+ AML) who cannot receive standard strong chemotherapy. It tests a new drug, tagraxofusp, added to two other drugs (venetoclax and azacitidine) to see if it helps more people achieve complete remission.…
Phase: PHASE2 • Sponsor: Stemline Therapeutics, Inc. • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
New combo therapy shows promise for older AML patients
Disease control OngoingThis study tests whether adding the drug selinexor to standard chemotherapy can help older adults with untreated acute myeloid leukemia (AML) live longer and achieve remission. About 57 participants will receive either standard chemo alone or chemo plus selinexor, followed by mai…
Phase: PHASE2 • Sponsor: Wake Forest University Health Sciences • Aim: Disease control
Last updated Aug 08, 2026 00:03 UTC
-
Stem cell transplant or drug combo: which better prevents leukemia return in seniors?
Disease control TerminatedThis study tests two strategies to keep acute myeloid leukemia (AML) from coming back in people aged 65 and older who have achieved remission after initial treatment. One group receives a stem cell transplant, while the other continues on a maintenance drug combination of azaciti…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New drug ONO-7428 enters first human tests for advanced cancers
Disease control OngoingThis early-phase study tests a new drug called ONO-7428 in about 60 adults with advanced solid tumors that have not responded to standard treatments. The main goal is to see if the drug is safe and tolerable, and to find the right dose. Participants will receive the drug and be m…
Phase: PHASE1 • Sponsor: Ono Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Personalized cancer attack: new trial matches drugs to tumor genes
Disease control OngoingThis phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…
Phase: PHASE2 • Sponsor: Hoffmann-La Roche • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New pill shows promise for Tough-to-Treat leukemias
Disease control OngoingThis study tests an oral drug called ONC201 in people whose acute leukemia or high-risk myelodysplastic syndrome (MDS) has returned or not responded to standard treatments. The trial has two phases: Phase I finds the safest dose, and Phase II checks if the drug shrinks or control…
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Could dropping one drug make stem cell transplants safer?
Disease control OngoingThis study looks at whether it is safe to remove one immune-suppressing drug, mycophenolate mofetil (MMF), from the standard treatment plan after a stem cell transplant for blood cancers. Sixty adults aged 18 to 75 will receive the transplant without MMF and be monitored for up t…
Phase: PHASE2 • Sponsor: Ronald Paquette • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
Can a pill target Hard-to-Treat bile duct cancers? a new drug puts FGFR2 mutations to the test
Disease control OngoingThis early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…
Phase: PHASE1 • Sponsor: Tyra Biosciences, Inc • Aim: Disease control
Last updated Aug 07, 2026 00:00 UTC
-
New antibody combo tested against hard-to-treat cancers
Disease control OngoingThis early-phase trial tests an experimental antibody called GEN1042, given alone or with the cancer drug pembrolizumab (and sometimes chemotherapy), in people with advanced solid tumors like lung, colon, melanoma, head and neck, or pancreatic cancer. The main goals are to check …
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New antibody combo shows promise in early cancer trial
Disease control OngoingThis trial tests a new antibody called acasunlimab, alone or with other cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The study has two parts: first to find safe doses, then to see how well those doses work. About 429 participa…
Phase: PHASE1, PHASE2 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New Immune-Boosting drug GEN1042 tested in japanese cancer patients
Disease control OngoingThis early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.
Phase: PHASE1 • Sponsor: Genmab • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New hope for Hard-to-Treat cancers: experimental PARP inhibitor enters human trials
Disease control OngoingThis study is testing an experimental drug called ACE-86225106 in adults with advanced solid tumors that are difficult to treat or have stopped responding to standard therapies. The drug works by blocking a protein that helps cancer cells repair themselves, potentially slowing or…
Phase: PHASE1, PHASE2 • Sponsor: Acerand Therapeutics (Shanghai) Limited • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Cancer drug brigimadlin tested for Long-Term use in solid tumour patients
Disease control OngoingThis study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…
Phase: PHASE2 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
New pill hopes to boost blood in bone marrow disease
Disease control OngoingThis study tests an experimental drug, HT-6184, in adults with a bone marrow disorder called myelodysplastic syndrome (MDS) who have low red blood cell counts (anemia). The goal is to see if the drug can improve blood counts and reduce the need for transfusions. Participants take…
Phase: PHASE2 • Sponsor: Halia Therapeutics, Inc. • Aim: Disease control
Last updated Aug 06, 2026 00:00 UTC
-
Immunotherapy combo shows promise against tough blood cancer in seniors
Disease control OngoingThis study tests whether adding an immunotherapy drug (pembrolizumab) to standard chemotherapy (azacitidine and venetoclax) can improve outcomes for older adults with newly diagnosed acute myeloid leukemia (AML) who cannot have intensive chemo. About 60 participants will be rando…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New drug combo shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests two drugs, veliparib and dinaciclib, in adults with advanced solid tumors that have spread and cannot be cured. The goal is to find the safest dose and understand side effects. About 121 participants will take part to see if this combination can slow …
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New hope for kids with rare cancers: targeted drug selpercatinib tested in phase 2 trial
Disease control OngoingThis phase 2 trial tests the drug selpercatinib in children and young adults (ages 1 to 21) with advanced cancers that have a specific genetic change called a RET alteration. The goal is to see if the drug can shrink tumors or stop them from growing. Only one participant has been…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
New combo aims to deepen remission in early CML
Disease control OngoingThis study tests whether adding ASTX727 to the standard drug dasatinib can better control chronic myeloid leukemia (CML) in newly diagnosed patients. About 70 adults with a specific genetic marker (Philadelphia chromosome) will receive both pills. The goal is to see if the combin…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Cancer drug regorafenib gets a second chance in small continuation study
Disease control OngoingThis study allows people with solid tumors who are already taking the cancer drug regorafenib in another Bayer study to keep taking it after that study ends. The goal is to see how safe and tolerable the continued treatment is. Only 13 participants are enrolled, and they take the…
Phase: PHASE2 • Sponsor: Bayer • Aim: Disease control
Last updated Aug 05, 2026 00:00 UTC
-
Can a new drug reduce bloodletting for polycythemia vera?
Disease control TerminatedThis trial investigates whether ropeginterferon alfa-2b can help people with polycythemia vera, a condition where the body makes too many red blood cells. The study will compare the drug to standard care, which includes phlebotomy (removing blood) and aspirin. About 70 adults wit…
Phase: PHASE4 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
New drug combo shows promise for tough cancers
Disease control OngoingThis early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 02, 2026 00:00 UTC
-
Which CML drug works best? new trial pits imatinib against dasatinib
Disease control OngoingThis phase 2 trial compares two standard CML drugs—imatinib (Gleevec) at two different doses and dasatinib (Sprycel)—in 406 newly diagnosed patients with chronic phase CML. The main goal is to see which treatment leads to the best molecular response after 12 months, meaning a ver…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Aug 01, 2026 00:00 UTC
-
DNA-Guided prescribing may shield young cancer patients from harmful drug reactions
Disease control OngoingThis trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …
Phase: NA • Sponsor: Murdoch Childrens Research Institute • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
New targeted therapy combo takes on tough leukemia
Disease control OngoingThis early-phase trial tests a new targeted drug called pivekimab sunirine (PVEK) alongside a standard chemotherapy regimen (FLAG-Ida) in 30 adults with newly diagnosed, high-risk acute myeloid leukemia or related blood cancers. PVEK works like a smart bomb, attaching to a protei…
Phase: PHASE1 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Radioactive therapy targets stubborn leukemia in early trial
Disease control OngoingThis study tests a new radioactive drug called [177Lu]Lu-PentixaTher in people with acute leukemia that has come back or not responded to standard treatments. The drug seeks out and delivers radiation directly to leukemia cells that have a specific marker (CXCR4). The main goals …
Phase: PHASE1, PHASE2 • Sponsor: Nantes University Hospital • Aim: Disease control
Last updated Jul 31, 2026 00:00 UTC
-
Cancer drug futibatinib gets a safety check in Long-Term rollover study
Disease control OngoingThis study is for people with advanced or metastatic cancer who have already been taking futibatinib in a previous study and are still benefiting from it. The goal is to keep giving them the drug (alone or with fulvestrant) and watch for any side effects over a longer period. Onl…
Phase: PHASE2, PHASE3 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jul 30, 2026 00:00 UTC
-
New CML drug combo strategy aims for deeper remission without lifelong side effects
Disease control OngoingThis study tests a new drug, asciminib, as the first treatment for adults newly diagnosed with chronic myeloid leukemia (CML). If the drug alone does not achieve a deep response within 2 to 3 years, a low dose of another targeted therapy is added. The goal is to see if this appro…
Phase: PHASE2 • Sponsor: University of Alabama at Birmingham • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a biologic drug outperform standard therapy for a rare blood cancer?
Disease control OngoingThis phase 3 trial compares the biologic drug P1101 (ropeginterferon alfa-2b) against the standard drug anagrelide in people with essential thrombocythemia, a rare blood cancer that causes too many platelets. The study enrolls adults who have not responded well to the first-line …
Phase: PHASE3 • Sponsor: PharmaEssentia • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Can a pill that starves tumors of oxygen help fight advanced cancer?
Disease control OngoingThis early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…
Phase: PHASE1 • Sponsor: Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Engineered donor cells aim to beat blood cancer without severe side effects
Disease control OngoingThis study tests a new way to treat children and young adults with high-risk blood cancers like leukemia and lymphoma. Doctors take blood cells from a family donor, remove certain T cells that can cause a harmful immune reaction, and then transplant the modified cells. The goal i…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
New pill targets genetic weakness in Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental oral drug called LY3410738 in people with advanced blood cancers such as acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) that have specific IDH1 or IDH2 gene mutations. The drug is designed to block the mutated IDH proteins that he…
Phase: PHASE1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jul 24, 2026 00:00 UTC
-
Spinal injection of dual immunotherapy plus chemotherapy targets cancer spread to brain lining
Disease control OngoingThis phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…
Phase: PHASE1, PHASE2 • Sponsor: Guangzhou Medical University • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Engineered donor cells take aim at tough blood cancers in early trial
Disease control TerminatedThis early-phase trial tests a new type of immune cell therapy called WU-CART-007 for people with certain blood cancers, including acute myeloid leukemia and T-cell lymphoma, that have come back or not responded to treatment. The therapy uses donor cells that are genetically modi…
Phase: PHASE1 • Sponsor: Washington University School of Medicine • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Personalized weight loss coaching could help cancer survivors shed pounds
Disease control OngoingThis study tests different levels of a telephone-based weight loss program for cancer survivors who are overweight or obese. All participants start with a core program including written materials, a smartphone app, and optional coaching. Those who lose at least 2% of their weight…
Phase: NA • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Can pressurized oxygen boost cord blood transplants?
Disease control OngoingThis study tests whether giving patients hyperbaric oxygen (breathing pure oxygen in a pressurized chamber) after an umbilical cord blood stem cell transplant helps the donated stem cells grow faster. The trial enrolls people with blood cancers like leukemia or lymphoma who lack …
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Could dead donors provide Life-Saving bone marrow?
Disease control OngoingThis early study is testing whether bone marrow from deceased donors can be safely used for transplants in people with blood cancers like leukemia and lymphoma. Twelve patients will receive the transplant along with chemotherapy or radiation. The main goal is to see if the new ma…
Phase: PHASE1, PHASE2 • Sponsor: Ossium Health, Inc. • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Targeted drug takes aim at NF1-Mutated cancers
Disease control OngoingThis phase II trial is testing the drug trametinib in 50 people with advanced cancers that have a specific genetic change called an NF1 mutation. Trametinib blocks certain proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from get…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Targeted drug aims to stop blood cancer return after transplant
Disease control OngoingThis phase 1 trial tests whether the drug tagraxofusp can help prevent relapse in people with certain blood cancers (acute myeloid leukemia, myelodysplastic syndrome, myelofibrosis, or chronic myelomonocytic leukemia) who have recently received a stem cell transplant. Participant…
Phase: PHASE1 • Sponsor: Karen Ballen, MD • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Experimental drug SHR-A2009 takes first steps against Hard-to-Treat cancers
Disease control OngoingThis early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how t…
Phase: PHASE1 • Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Can a drug free myelofibrosis patients from frequent blood transfusions?
Disease control OngoingThis phase 3 study tests whether the drug luspatercept can help people with myelofibrosis-related anemia become independent of red blood cell transfusions. Participants are adults with myelofibrosis who are already taking a JAK inhibitor and need regular transfusions. The study c…
Phase: PHASE3 • Sponsor: Celgene • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
New drug cocktail targets advanced cancers in early trial
Disease control OngoingThis Phase I trial tests the safety and best dose of combining vorinostat with one of three mTOR inhibitors (sirolimus, everolimus, or temsirolimus) in up to 249 patients with advanced cancer that has not responded to standard treatments. The drugs aim to block cancer cell growth…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Epigenetic drugs aim to stop cancer return after transplant in kids
Disease control OngoingThis trial tests whether adding two drugs—vorinostat and low-dose azacitidine—after a stem cell transplant can help prevent relapse in children with certain myeloid cancers. The study includes children aged 1 to 21 with acute myeloid leukemia or related conditions. Researchers ar…
Phase: PHASE1 • Sponsor: Johns Hopkins All Children's Hospital • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug SG1827 enters first human tests for Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new drug, SG1827, in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. The main goals are to check the drug's safety, find the best dose, and get a first look at whether it c…
Phase: PHASE1 • Sponsor: Hangzhou Sumgen Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 17, 2026 00:00 UTC
-
New drug targets Hard-to-Treat cancers in japanese patients
Disease control OngoingThis study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…
Phase: PHASE1, PHASE2 • Sponsor: Gilead Sciences • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Lab-Grown stem cells could speed immune recovery in blood cancer transplants
Disease control OngoingThis phase 2 trial tests whether adding lab-grown umbilical cord blood cells (dilanubicel) to a standard cord blood transplant helps people with blood cancers like leukemia recover their blood and immune cells faster. Participants receive chemotherapy and radiation to prepare the…
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Oral chemotherapy candidate utidelone moves to human testing for advanced cancers
Disease control OngoingThis early-stage trial evaluates the safety, tolerability, and how well the body absorbs utidelone in capsule form for people with advanced solid tumors, including metastatic breast cancer. The study has three parts: finding the safest dose, comparing the capsule to the injected …
Phase: PHASE1 • Sponsor: Beijing Biostar Pharmaceuticals Co., Ltd. • Aim: Disease control
Last updated Jul 12, 2026 00:00 UTC
-
Targeted drug palbociclib tested against cancers with specific genetic flaw
Disease control OngoingThis phase II trial is testing the drug palbociclib in 40 patients whose advanced cancers have extra copies of the CCND1, 2, or 3 genes. Palbociclib blocks proteins that help cancer cells grow. The goal is to see if the drug can shrink tumors or stop them from growing. The study …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 11, 2026 00:00 UTC
-
Experimental drug COH29 targets tumor growth enzyme in advanced cancers
Disease control OngoingThis early-phase trial tests an experimental drug called COH29 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard therapy available. COH29 works by blocking an enzyme that cancer cells need to grow and multiply. The main g…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
Pushing a weighted sled may help cancer patients build muscle and lose fat
Disease control OngoingThis pilot study tests whether a resistance training program using weighted sled pushes and pulls can help cancer patients improve muscle mass and reduce body fat. Thirty adults aged 20-89 with a cancer diagnosis will participate in monitored exercise sessions over six months. Re…
Sponsor: Allegheny Singer Research Institute (also known as Allegheny Health Network Research Institute) • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New drug aims to boost immune system against advanced cancers
Disease control OngoingThis early-stage study tests a new drug called IOA-244 in about 210 adults with advanced or metastatic cancers like lung cancer, melanoma, and lymphoma. The main goal is to see if the drug is safe and tolerable, both alone and combined with other treatments. Researchers also chec…
Phase: PHASE1 • Sponsor: iOnctura • Aim: Disease control
Last updated Jul 10, 2026 00:00 UTC
-
New immunotherapy combo tested in kids with Hard-to-Treat cancers
Disease control OngoingThis study is testing two immunotherapy drugs, durvalumab and tremelimumab, in children and teens up to age 17 with advanced solid tumors or blood cancers that have not responded to standard treatments. The first part finds the safest dose, and the second part checks if the drugs…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New drug combo targets Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called WJ47156, alone or combined with other anti-cancer drugs, in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see early signs of tumor shrink…
Phase: PHASE1 • Sponsor: Shanghai Junshi Bioscience Co., Ltd. • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
Experimental combo targets hard-to-treat blood cancers
Disease control OngoingThis early-phase study tests two drugs—guadecitabine and atezolizumab—together in adults with myelodysplastic syndrome or chronic myelomonocytic leukemia that has come back or not responded to prior therapy. The goal is to find the safest dose and see if the combination can shrin…
Phase: PHASE1, PHASE2 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jul 09, 2026 00:00 UTC
-
New oral drug targets Tough-to-Treat leukemia
Disease control TerminatedThis early-stage trial tests an experimental oral drug called GB3226 in adults with acute myeloid leukemia (AML) that has come back or not responded to treatment. The drug works by blocking two pathways that help leukemia cells grow. The study aims to find a safe dose and check f…
Phase: PHASE1 • Sponsor: Galecto Biotech AB • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Supercharged immune cells take aim at childhood cancers
Disease control OngoingThis study tests a new type of immunotherapy for people with cancers that have returned or not responded to treatment, such as neuroblastoma, sarcoma, and certain other solid tumors. The treatment uses a patient's own T cells, which are genetically modified to recognize a protein…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
New drug cocktail aims to improve remission in older leukemia patients
Disease control OngoingThis phase I trial tests the safety of adding ruxolitinib to a standard combination of dasatinib and dexamethasone for adults aged 40 and older with newly diagnosed Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph+ ALL). The study starts with a low dose of ruxoli…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Radioactive antibody hones in on cancer cells to boost transplant success
Disease control OngoingThis trial tests whether adding a radioactive antibody (90Y-DOTA-anti-CD25 basiliximab) to standard chemotherapy and targeted radiation can better prepare the bone marrow for a stem cell transplant in people with high-risk acute leukemia or myelodysplastic syndrome. The antibody …
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 08, 2026 00:00 UTC
-
Engineered t cells with a kill switch aim to make stem cell transplants safer
Disease control OngoingThis study tests a new approach for people receiving a stem cell transplant from a partially matched family donor. The donor's immune cells (T cells) are modified in the lab to include a 'suicide gene' that can be activated by a drug if the cells attack the patient's body, causin…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New combo therapy shows promise for older leukemia patients
Disease control OngoingThis study tested a combination of two drugs, azacitidine and gemtuzumab ozogamicin, in 133 older adults (age 60+) with untreated acute myeloid leukemia. The goal was to see how well the treatment could put the cancer into remission and improve survival. The approach uses chemoth…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Suicide Gene-Equipped t cells aim to make stem cell transplants safer
Disease control OngoingThis trial tests whether specially modified T cells from a partially matched donor can help patients recover their immune system faster after a stem cell transplant. The T cells are engineered with a 'suicide gene' that allows doctors to destroy them if they cause graft-versus-ho…
Phase: PHASE1 • Sponsor: Baylor College of Medicine • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
Precision radiation may boost stem cell transplant success in tough leukemias
Disease control OngoingThis study tests a precise radiation method called total marrow and lymphoid irradiation (TMLI) given with two chemotherapy drugs (etoposide and cyclophosphamide) before a donor stem cell transplant. The goal is to safely deliver higher radiation doses to the bone marrow to wipe …
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jul 03, 2026 00:00 UTC
-
New drug combo aims to tackle Hard-to-Treat cancers
Disease control TerminatedThis study tests a combination of two drugs, neratinib and valproate, in people with advanced solid tumors that have not responded to standard treatments. The first part finds the safest dose, and the second part focuses on cancers with a RAS mutation, like certain colon and panc…
Phase: PHASE1, PHASE2 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Childhood leukaemia trial seeks best chemo cocktail
Disease control OngoingThis trial investigates the best way to treat children with acute myeloid leukaemia (AML) by comparing different chemotherapy drugs and doses. It tests whether adding up to three doses of the targeted drug gemtuzumab ozogamicin to standard chemo is safe and effective. The study a…
Phase: PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Cancer-Killing virus injected directly into tumors shows promise in Mid-Stage trial
Disease control OngoingThis study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…
Phase: PHASE2 • Sponsor: EpicentRx, Inc. • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
New combo aims to boost survival in older AML patients
Disease control OngoingThis phase 3 trial compares a two-drug combination (pevonedistat plus azacitidine) against azacitidine alone in 302 older or unfit adults newly diagnosed with acute myeloid leukemia (AML) who cannot have standard intensive chemotherapy. The main goal is to see if the combination …
Phase: PHASE3 • Sponsor: PETHEMA Foundation • Aim: Disease control
Last updated Jun 27, 2026 14:03 UTC
-
New drug combo aims to outsmart resistant cancers
Disease control OngoingThis early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New drug candidate targets Hard-to-Treat blood cancers
Disease control OngoingThis study tests an experimental drug called LY2784544 in people with three types of blood cancers known as myeloproliferative neoplasms: polycythemia vera, essential thrombocythemia, and myelofibrosis. The trial enrolls patients who have not responded to, cannot tolerate, or hav…
Phase: PHASE2 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
Can a targeted drug boost chemo for hard-to-treat blood cancers?
Disease control OngoingThis phase II trial tested whether adding veliparib (a targeted drug) to standard chemotherapy (topotecan and carboplatin) helps people with advanced myeloproliferative disorders, acute myeloid leukemia, or chronic myelomonocytic leukemia. The study enrolled 25 adults whose cance…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New antibody drug takes on advanced tumors in first human trial
Disease control OngoingThis early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…
Phase: PHASE1 • Sponsor: Institut Paoli-Calmettes • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
New stem cell transplant approach aims to tame deadly bone marrow cancer
Disease control OngoingThis early-phase trial tests a reduced-intensity stem cell transplant using a half-matched donor and a drug called cyclophosphamide after the transplant to prevent rejection. The goal is to see if this approach is safe enough for patients with advanced myelofibrosis, a serious bo…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Momelotinib access expanded for myelofibrosis patients in Long-Term safety study
Disease control OngoingThis study provides extended access to the drug momelotinib for 237 people with a type of bone marrow cancer called myelofibrosis. Participants had already been taking momelotinib in earlier studies and had not seen their disease get worse. The goal is to see how safe the drug is…
Phase: PHASE2 • Sponsor: GlaxoSmithKline • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered virus targets Hard-to-Treat cancers in early trial
Disease control ENROLLING_BY_INVITATIONThis early-phase trial tests an experimental virus-based treatment called IDOV-Immune in people with advanced solid tumors that have stopped responding to standard treatments. The virus is designed to infect and destroy cancer cells while leaving healthy cells alone. The study fo…
Phase: EARLY_PHASE1 • Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost immune attack on Hard-to-Treat cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and monalizumab, in about 383 adults with advanced solid tumors, including colorectal cancer. The goal is to see if the combination is safe and can shrink tumors. Some participants also receive standard chemotherapy or other ta…
Phase: PHASE1, PHASE2 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to improve leukemia treatment in young adults
Disease control ENROLLING_BY_INVITATIONThis clinical trial compares three different chemotherapy regimens for young adults (ages 18-65) newly diagnosed with low-risk acute myeloid leukemia (AML). One regimen includes a new drug called lisaftoclax combined with standard chemotherapy drugs. The study aims to see which c…
Phase: PHASE2, PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New targeted therapy hopes to shrink Hard-to-Treat ovarian cancers
Disease control OngoingThis study tests a drug called mirvetuximab soravtansine in Japanese patients with advanced ovarian cancer or other solid tumors that have a specific protein (folate receptor alpha). The drug is designed to target and kill cancer cells while sparing healthy ones. The trial has tw…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New drug combo aims to boost survival in aggressive leukemia
Disease control ENROLLING_BY_INVITATIONThis study tests three different chemotherapy regimens in 450 young adults (ages 15-65) with intermediate- or high-risk acute myeloid leukemia (AML). All regimens include the experimental drug lisaftoclax plus standard chemotherapies. The main goal is to see which combination lea…
Phase: PHASE2, PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for kids with resistant tumors: drug combo enters safety trial
Disease control OngoingThis early-stage study tests a combination of two drugs, avutometinib and defactinib, in children and young adults (ages 3 to 30) with advanced or recurrent solid tumors that have specific genetic changes. The main goal is to find the safest dose with the fewest side effects. The…
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New cocktail therapy aims to beat back stubborn leukemia
Disease control OngoingThis phase 2 trial tests a combination of six drugs, called the Beach regimen, in 32 adults with relapsed or refractory acute myeloid leukemia (AML). The goal is to see if this mix can bring about remission and improve survival. Participants receive the drugs in a specific schedu…
Phase: PHASE2 • Sponsor: Liping Dou • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New hope for tough leukemia: Triple-Drug attack under study
Disease control OngoingThis early-phase trial tests a new drug called navtemadlin (KRT-232) combined with two standard drugs (decitabine and venetoclax) for people with acute myeloid leukemia (AML) that has come back, not responded to treatment, or is newly diagnosed. The main goal is to find the safes…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Gentler chemo approach shows promise for tough blood cancers in older patients
Disease control OngoingThis study looks at whether lower doses of the chemotherapy drug CPX-351 can help older patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) that have come back or not responded to other treatments. The goal is to control the disease while being gentler o…
Phase: PHASE2 • Sponsor: Case Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy boosts chemo to wipe out hidden leukemia cells
Disease control OngoingThis phase 2 trial tests whether adding the immunotherapy drug pembrolizumab to standard chemotherapy helps people with newly diagnosed acute myeloid leukemia (AML) achieve a deeper remission. About 49 participants will receive either chemo alone or chemo plus pembrolizumab. The …
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Promising combo offers hope for older AML patients
Disease control OngoingThis phase 3 study tested whether adding venetoclax to azacitidine helps people with untreated acute myeloid leukemia (AML) who cannot receive standard chemotherapy. About 443 adults took part, with two-thirds receiving the drug combo and one-third getting a placebo plus azacitid…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Experimental cell therapy aims to fight advanced cancers
Disease control TerminatedThis study was designed to test a new treatment called GT307 for people with advanced solid tumors that have spread or come back after standard therapy. GT307 uses a patient's own immune cells (tumor-infiltrating lymphocytes) to attack the cancer. The main goals were to check saf…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
New immunotherapy flotetuzumab tested in kids with Tough-to-Treat leukemia
Disease control OngoingThis early-phase trial is testing a drug called flotetuzumab in children and young adults with acute myeloid leukemia (AML) that has returned or not responded to standard treatment. Flotetuzumab is an immunotherapy designed to help the body's immune cells find and attack cancer c…
Phase: PHASE1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 13:05 UTC
-
Could a platelet-boosting drug improve blood counts in certain blood cancers?
Disease control TerminatedThis phase 2 trial tests whether eltrombopag, a drug already approved for other blood disorders, can improve blood cell counts in people with low-risk myelodysplastic syndromes (MDS) or chronic myelomonocytic leukemia (CMML) who have a mutation in the TET2 gene. Participants take…
Phase: PHASE2 • Sponsor: Abhay Singh, MD MPH • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
New cancer drug injected into tumors shows promise in early trial
Disease control TerminatedThis early study tests a new drug called BI 3923948, given as injections into the tumor, either alone or with a checkpoint inhibitor (ezabenlimab) given by IV. It includes about 60 adults with advanced solid tumors that have spread and are not responding to other treatments. The …
Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Promising leukemia combo trial pulled before it began
Disease control TerminatedThis study aimed to find a safe dose of revumenib when given with standard chemotherapy drugs for children and young adults with acute leukemia. It was designed for patients with certain genetic markers. However, the trial was withdrawn before any participants were enrolled, so n…
Phase: PHASE1 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
Gene test may help pick better donors for leukemia patients
Disease control OngoingThis study looks at whether choosing stem cell donors based on certain genes (KIR) in addition to standard matching can reduce the chance of leukemia returning after a bone marrow transplant. About 511 people with acute myeloid leukemia (AML) are taking part. Doctors will test do…
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug combo aims to prevent transplant complications in blood cancer patients
Disease control OngoingThis study tests whether adding the drug itacitinib to the usual two-drug regimen (cyclophosphamide and tacrolimus) can better prevent graft-versus-host disease (GVHD) in people receiving stem cell transplants for blood cancers. GVHD is a serious complication where donor cells at…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Donor stem cell transplant shows promise for tough blood cancers
Disease control OngoingThis study tests a stem cell transplant from a matched unrelated donor for people with advanced blood cancers or blood disorders. Patients get chemotherapy and radiation before the transplant to prepare their body, then take drugs to prevent the donor cells from attacking their o…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail shows promise for Hard-to-Treat leukemia
Disease control OngoingThis early-stage study tested a combination of three immunotherapy drugs (blinatumomab, nivolumab, and ipilimumab) in 28 adults with a severe form of B-cell leukemia that had returned or not responded to prior treatments. The main goal was to find safe doses and identify side eff…
Phase: PHASE1 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
Immune cell booster for leukemia patients pulled before start
Disease control TerminatedThis study aimed to see if giving special immune cells (γδ T cells) after a stem cell transplant could help prevent leukemia from coming back in high-risk patients. It was planned for adults aged 18-65 with acute myeloid leukemia. However, the study was withdrawn before any parti…
Phase: EARLY_PHASE1 • Sponsor: Guangzhou Bio-gene Technology Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:39 UTC
-
New drug combo shows promise for genetic subtype of leukemia
Disease control OngoingThis early-stage trial tests two new targeted drugs (AG-120 and AG-221) given alongside standard chemotherapy for people with a specific genetic form of acute myeloid leukemia (AML). The study includes about 153 adults with newly diagnosed AML that has an IDH1 or IDH2 mutation. T…
Phase: PHASE1 • Sponsor: Institut de Recherches Internationales Servier • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC
-
New drug combo shows promise against tough cancers
Disease control OngoingThis early-stage study tests a new drug called MEDI5752, given alone or with chemotherapy, in adults with advanced solid tumors that have not responded to other treatments. The main goals are to check safety, find the right dose, and see if the drug can shrink tumors. About 400 p…
Phase: PHASE1 • Sponsor: MedImmune LLC • Aim: Disease control
Last updated Jun 27, 2026 12:35 UTC
-
New hope for elderly leukemia patients: which chemo works best?
Disease control OngoingThis study aims to find the safest and most effective initial chemotherapy for older adults (60-75) newly diagnosed with acute myeloid leukemia who can handle strong treatment. About 90 participants will be randomly assigned to one of two drug combinations or a standard treatment…
Phase: NA • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
Virus therapy takes on Hard-to-Treat cancers
Disease control OngoingThis early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…
Phase: PHASE1 • Sponsor: National Medical Research Radiological Centre of the Ministry of Health of Russia • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New chemo cocktail aims to boost survival in elderly leukemia patients
Disease control OngoingThis phase 2 trial tests two different chemotherapy combinations in adults aged 60-75 with acute myeloid leukemia (AML). One group gets a standard drug combo plus venetoclax (DAV/IAV), while the other gets a newer combo with homoharringtonine (HAV). The goal is to see which regim…
Phase: PHASE2 • Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
Blood cancer drug venetoclax gets Long-Term safety check
Disease control OngoingThis study gives venetoclax to people with certain blood cancers who already benefited from it in earlier studies. The main goal is to track side effects and safety over a longer period. About 165 participants will continue taking the drug to see how well it works and how safe it…
Phase: PHASE3 • Sponsor: AbbVie • Aim: Disease control
Last updated Jun 27, 2026 12:33 UTC
-
New drug duo aims to outsmart stubborn cancers
Disease control OngoingThis early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…
Phase: PHASE1 • Sponsor: Royal Marsden NHS Foundation Trust • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
Drug combo shows promise in early ovarian cancer trial
Disease control OngoingThis early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …
Phase: PHASE1 • Sponsor: Virginia Commonwealth University • Aim: Disease control
Last updated Jun 27, 2026 12:32 UTC
-
New combo therapy for AML enters early human testing
Disease control OngoingThis early-phase study tests a new drug called cusatuzumab alongside usual treatments for adults with acute myeloid leukemia (AML) who cannot have intensive chemotherapy. The main goal is to check the safety and side effects of the combination. About 61 participants will receive …
Phase: PHASE1 • Sponsor: OncoVerity, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New vaccine trial aims to train immune system against leukemia after transplant
Disease control OngoingThis early-phase study tests a custom-made cancer vaccine (DC/AML fusion vaccine) for people with acute myeloid leukemia (AML) who have recently had a stem cell transplant. The vaccine is designed to teach the body's immune cells to recognize and attack remaining leukemia cells. …
Phase: PHASE1 • Sponsor: Beth Israel Deaconess Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for Hard-to-Treat cancers: DB-1305 enters human trials
Disease control OngoingThis study tests a new drug called DB-1305/BNT325 in adults with advanced solid tumors that have not responded to standard treatments. The goal is to find a safe dose and see if it can shrink tumors. About 1,100 participants will take part in this early-phase trial.
Phase: PHASE1, PHASE2 • Sponsor: DualityBio Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New hope for hard-to-treat blood cancers: experimental drug imetelstat tested in phase 2 trial
Disease control OngoingThis study tests an experimental drug called imetelstat in 46 adults with high-risk myelodysplastic syndromes or acute myeloid leukemia that did not improve after standard therapy. The goal is to see if the drug can improve blood cell counts and control the disease. Participants …
Phase: PHASE2 • Sponsor: GCP-Service International West GmbH • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
New drug ZW191 targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests a new drug called ZW191 in people with advanced solid tumors, including ovarian, endometrial, and non-small cell lung cancers. The drug is designed to target a protein on cancer cells and deliver a toxic payload. The main goals are to check safety, fi…
Phase: PHASE1 • Sponsor: Zymeworks BC Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:30 UTC
-
Promising leukemia drug tested as maintenance after transplant in kids
Disease control TerminatedThis study was designed to test the safety and best dose of the drug revumenib in children and young adults with certain types of leukemia (ALL, AML, or mixed phenotype) after they have received a stem cell transplant. The goal was to see if revumenib could help prevent the cance…
Phase: PHASE1 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New drug LP-184 tested on tough cancers: hope for Late-Stage patients
Disease control OngoingThis study tests a new drug called LP-184 in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to find a safe dose and see if the drug can shrink tumors or slow their growth. About 64 participants will receive the drug as an…
Phase: PHASE1, PHASE2 • Sponsor: Lantern Pharma Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New hope for older blood cancer patients: smarter transplants aim to cut relapse
Disease control OngoingThis clinical trial is testing different treatment strategies to improve outcomes for older adults with acute myeloid leukemia (AML) or high-risk myelodysplastic syndrome (MDS) who are getting a stem cell transplant. The study compares a new pre-transplant drug (Vyxeos) with stan…
Phase: PHASE2, PHASE3 • Sponsor: University of Birmingham • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New cocktail of cancer drugs shows promise in early leukemia trial
Disease control OngoingThis early-phase trial is testing whether adding the drug venetoclax to a standard treatment regimen can help adults with a specific type of leukemia (Philadelphia chromosome-positive ALL). The study involves 20 participants and aims to find the safest dose of venetoclax when com…
Phase: PHASE1 • Sponsor: OHSU Knight Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New stem cell method shows promise for young blood cancer patients
Disease control OngoingThis study tests a new way to do stem cell transplants for children and young adults (up to age 22) with blood cancers like leukemia. Doctors remove certain immune cells from donated stem cells to lower the risk of graft-versus-host disease, a serious complication. The goal is to…
Phase: PHASE2 • Sponsor: Julie-An M. Talano • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
Shorter treatment course may ease side effects for AML patients
Disease control OngoingThis study tests a new way of giving two drugs—venetoclax and azacitidine—to adults with acute myeloid leukemia (AML) who are not healthy enough for standard chemotherapy. Instead of the usual 7 days of azacitidine, this approach uses only 5 days per cycle to try to reduce infect…
Phase: PHASE2 • Sponsor: University of Leipzig • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New pill plus chemo shows promise in early AML trial
Disease control OngoingThis phase 2 trial tests a new targeted drug called sonrotoclax (taken as a pill) combined with standard chemotherapy in 47 adults newly diagnosed with acute myeloid leukemia (AML). The treatment plan is adjusted based on each patient's genetic risk and response. The goal is to s…
Phase: PHASE2 • Sponsor: Shanghai Jiao Tong University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 12:26 UTC
-
Leukemia drug breakthrough: study tests tapering strategy to free patients from daily pills
Disease control OngoingThis study looks at whether people with chronic myeloid leukemia (CML) can stop taking their daily targeted therapy (TKI) without the cancer coming back. It compares two approaches: stopping the drug suddenly after a year of normal dosing, versus slowly reducing the dose over a y…
Phase: PHASE3 • Sponsor: Poitiers University Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Experimental cell therapy for advanced gynecological cancers halted before start
Disease control TerminatedThis study aimed to test an experimental treatment called GT316, made from a patient's own immune cells (tumor-infiltrating lymphocytes), for advanced gynecological cancers. The goal was to check the safety and side effects of this cell therapy. However, the study was withdrawn b…
Phase: NA • Sponsor: Grit Biotechnology • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Tiny paclitaxel particles aim to hit tumors harder
Disease control OngoingThis early-phase trial tests a new form of the chemotherapy drug paclitaxel, called FID-007, in 50 people with advanced solid tumors that have stopped responding to other treatments. The drug is wrapped in a special polymer to make it smaller, which may help it reach deeper into …
Phase: PHASE1 • Sponsor: University of Southern California • Aim: Disease control
Last updated Jun 27, 2026 12:25 UTC
-
Could a chemo drug help patients with rare bone marrow cancer?
Disease control OngoingThis phase II trial tests the drug decitabine in 21 patients with advanced myelofibrosis, a bone marrow cancer that causes scarring and anemia. The goal is to see if decitabine can improve blood counts and reduce the need for transfusions. Researchers are also monitoring side eff…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
Promising drug for immunotherapy side effects never tested: trial withdrawn
Disease control TerminatedThis phase II trial aimed to test the drug itacitinib in people with severe side effects from cancer immunotherapy that did not get better with steroids. The goal was to see if itacitinib could calm the overactive immune response causing these side effects. However, the study was…
Phase: PHASE2 • Sponsor: Douglas Johnson • Aim: Disease control
Last updated Jun 27, 2026 12:24 UTC
-
New combo therapy aims to boost immunotherapy in Hard-to-Treat cancers
Disease control OngoingThis study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…
Phase: PHASE2 • Sponsor: Centre Leon Berard • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New drug duo takes on advanced cancers in early trial
Disease control OngoingThis study tests two experimental drugs, AK127 and AK112, together in people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and see if the combination can shrink tumors. About 216 adults aged 18 to 75 with good perfor…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New strategy aims to boost chemo power in childhood leukemia
Disease control OngoingThis phase II trial tests whether giving a short course of azacitidine or decitabine before standard chemotherapy can improve outcomes for children with newly diagnosed acute myeloid leukemia (AML). The study enrolls 206 participants and focuses on tolerability, changes in DNA me…
Phase: PHASE2 • Sponsor: St. Jude Children's Research Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New antibody takes aim at Hard-to-Treat cancers
Disease control OngoingThis Phase 2 trial is testing a drug called PRL3-zumab in 60 people with advanced solid tumors that have not responded to standard treatments. PRL3-zumab is an antibody designed to attach to a protein called PRL3 found on cancer cells, potentially helping the immune system attack…
Phase: PHASE2 • Sponsor: Intra-IMMUSG Pte Ltd • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New hope for tough leukemia: drug cocktail targets resistant cancer
Disease control OngoingThis early-phase study tests a three-drug combination (navitoclax, venetoclax, and decitabine) in adults and teens with acute myeloid leukemia that returned or didn't respond to previous treatment. The goal is to find the safest dose and see if the combo can shrink or control the…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
New cancer drug ALK-N001 enters early human testing
Disease control TerminatedThis early-phase trial tests a new drug called ALK-N001 in people with advanced solid tumors, including esophageal, lung, and stomach cancers. The main goals are to check safety, find the right dose, and see how the drug moves through the body. Only 16 participants were enrolled,…
Phase: PHASE1 • Sponsor: Zhejiang Anglikang Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New pill targets gene flaws in hard-to-treat bile duct cancer
Disease control OngoingThis study tests an experimental drug called CGT4859 in people with bile duct cancer or other advanced solid tumors that have specific changes in the FGFR2 or FGFR3 genes. The drug is designed to block these faulty genes and slow tumor growth. About 110 adults who have already tr…
Phase: PHASE1, PHASE2 • Sponsor: Cogent Biosciences, Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:09 UTC
-
New combo aims to keep leukemia away after remission
Disease control ENROLLING_BY_INVITATIONThis study tests whether adding venetoclax to standard chemotherapy (cytarabine) can help adults with acute myeloid leukemia (AML) stay in remission longer. About 232 participants who are already in remission will receive either the combination or chemo alone. The main goal is to…
Phase: PHASE2, PHASE3 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Custom-Made cancer vaccine shows promise in early trial
Disease control OngoingThis early-phase trial tests a personalized immunotherapy called MVX-ONCO-2 for people with advanced solid tumors that have not responded to standard treatments. The vaccine is made from the patient's own tumor cells and aims to boost the immune system to fight the cancer. The st…
Phase: PHASE1 • Sponsor: University Hospital, Geneva • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Stem cell study to prevent transplant complications pulled before start
Disease control TerminatedThis study aimed to see if a special type of stem cell (hAESC) could safely prevent acute graft-versus-host disease in people receiving a stem cell transplant for blood cancer. It was designed for adults at high risk of this complication. However, the study was withdrawn before a…
Phase: PHASE1 • Sponsor: Nanfang Hospital, Southern Medical University • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
New transplant method aims to reduce dangerous immune reactions
Disease control OngoingThis study tests a stem cell transplant method for people with blood cancers like leukemia or lymphoma. The approach uses chemotherapy, total body radiation, and a drug called cyclophosphamide after the transplant to prevent graft-versus-host disease, where donor cells attack the…
Phase: PHASE1, PHASE2 • Sponsor: Roswell Park Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Cancer patients get continued access to promising drug
Disease control OngoingThis study allows people with advanced cancers who are already benefiting from the drug ribociclib in a previous Novartis trial to keep receiving it. The goal is to provide continued access and monitor how long they stay on treatment and any side effects. Only 22 patients are enr…
Phase: PHASE2 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 12:07 UTC
-
Drug combo shows promise against rare bone marrow cancer
Disease control OngoingThis study tests whether combining ruxolitinib and thalidomide can shrink the cancer and improve symptoms in 30 people with myelofibrosis, a rare bone marrow disease. Participants include those who have not responded to prior treatment or are newly diagnosed with higher-risk dise…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:06 UTC
-
New combo shows promise for Tough-to-Treat leukemia
Disease control ENROLLING_BY_INVITATIONThis study tests a combination of three drugs (homoharringtonine, venetoclax, and azacitidine) in 40 adults newly diagnosed with a rare and aggressive leukemia called mixed-phenotype acute leukemia (MPAL). The goal is to see if this drug combo can safely help more patients achiev…
Phase: PHASE2 • Sponsor: Guangdong Second Provincial General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Younger donors may improve stem cell transplant success for leukemia patients
Disease control OngoingThis study compares stem cell transplants from two types of donors for people with leukemia or myelodysplastic syndromes (MDS): younger non-family members (age 40 or under) and older first-degree relatives (over 50). The goal is to see which donor leads to better overall survival…
Phase: PHASE3 • Sponsor: First Affiliated Hospital of Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 12:05 UTC
-
Armored immune cells take on tough blood cancers in early trial
Disease control OngoingThis early-phase study tests the safety of specially engineered immune cells (armored CAR T cells) in people with certain blood cancers that have not responded to standard treatments. The cells are made from the patient's own blood and designed to better target and attack cancer …
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Could a probiotic help stem cell transplant recovery?
Disease control OngoingThis early-phase trial tests whether a probiotic called CBM588 is safe and can improve outcomes in 36 patients who have received a donor stem cell transplant. The probiotic aims to increase healthy gut bacteria and reduce gut-related side effects like diarrhea and colon inflammat…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:04 UTC
-
Parent stem cells offer new hope for kids with blood cancer
Disease control OngoingThis study tests a new way to do stem cell transplants for 20 children with blood cancers or myelodysplasia who don't have a perfect donor match. Doctors remove certain immune cells from a parent's partially matched stem cells before transplant to help the new cells grow faster a…
Phase: PHASE1, PHASE2 • Sponsor: Nationwide Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
Keytruda takes on genetic weak spots in advanced tumors
Disease control OngoingThis phase 2 trial tests whether pembrolizumab (Keytruda) can shrink or control advanced solid tumors that have certain gene mutations (BRCA1, BRCA2, POLE, POLD1). The study enrolled 21 adults with cancers that have spread or come back. Researchers measure how many patients see t…
Phase: PHASE2 • Sponsor: Rutgers, The State University of New Jersey • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New Two-Drug immune attack launched against tough cancers
Disease control OngoingThis early-phase study tests two experimental immunotherapy drugs — botensilimab and balstilimab — alone and together in people with advanced solid tumors that have stopped responding to standard treatments. The main goals are to check safety, find the right dose, and look for ea…
Phase: PHASE1 • Sponsor: Agenus Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:03 UTC
-
New hope for kids with relapsed AML: targeted drug combo trial opens
Disease control OngoingThis study tests an experimental drug called quizartinib, given with chemotherapy, for children and young adults (ages 1 month to 21 years) whose acute myeloid leukemia (AML) has returned or not responded to treatment. The goal is to see if the combination is safe and can help co…
Phase: PHASE1, PHASE2 • Sponsor: Daiichi Sankyo • Aim: Disease control
Last updated Jun 27, 2026 12:02 UTC
-
Can a pill keep blood cancer away after transplant?
Disease control OngoingThis phase 1 trial tests whether the oral drug Inqovi (decitabine/cedazuridine) can help prevent myelodysplastic syndrome (MDS) or chronic myelomonocytic leukemia (CMML) from returning after a stem cell transplant. About 22 adults who have had a reduced-intensity transplant will …
Phase: PHASE1 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
Precision radiation may boost second stem cell transplants for relapsed blood cancers
Disease control TerminatedThis early-stage trial tests a precise type of radiation (IMTMI) given with chemotherapy before a second donor stem cell transplant for people with advanced blood cancers that have returned. The goal is to find the safest dose and see if it can reduce side effects and prevent the…
Phase: PHASE1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New immunotherapy combo tested for incurable cancers
Disease control OngoingThis study tests two immunotherapy drugs, durvalumab and tremelimumab, alone or together with standard chemotherapy in people with advanced solid tumors that cannot be cured. The main goal is to find the highest safe dose that does not cause severe side effects. About 153 partici…
Phase: PHASE1 • Sponsor: Canadian Cancer Trials Group • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New hope for older leukemia patients: drug may keep cancer away after transplant
Disease control OngoingThis phase 2 study tests whether the drug ruxolitinib can help prevent acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) from coming back after a stem cell transplant. About 64 older adults in remission will take ruxolitinib as maintenance therapy. The goal is to see…
Phase: PHASE2 • Sponsor: Massachusetts General Hospital • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo targets tough leukemia cases
Disease control OngoingThis early-stage trial tests the safety and best dose of combining two drugs—everolimus and midostaurin—for people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) that has come back or is hard to treat. The drugs work by blocking faulty signals that help cance…
Phase: PHASE1 • Sponsor: Richard Stone, MD • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New hope for advanced cancer? early trial of 3D185 begins
Disease control OngoingThis early-phase study tests a new drug called 3D185 in 42 adults with advanced solid tumors who have run out of standard treatments. The main goals are to check the drug's safety and how the body processes it, while also looking for any signs that it might shrink tumors. This is…
Phase: PHASE1 • Sponsor: 3D Medicines (Beijing) Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
New cancer drug ASTX660 tested in patients with no other options
Disease control OngoingThis study tests a new drug called ASTX660 in people with advanced solid tumors or lymphomas that have not responded to standard treatments. The trial has two phases: first, to find the safest dose and check for side effects, and second, to see if the drug can shrink tumors or co…
Phase: PHASE1, PHASE2 • Sponsor: Taiho Oncology, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control TerminatedThis study tests an oral drug called emavusertib (CA-4948) in adults with acute myeloid leukemia (AML) or a high-risk bone marrow disorder (MDS) that have not responded to or returned after prior treatment. The goal is to find the safest and most effective dose and to see if the …
Phase: PHASE1, PHASE2 • Sponsor: Curis, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Can an enzyme shield the gut during transplant recovery?
Disease control OngoingThis study tests an oral enzyme called SYN-004 in adults who have received a stem cell transplant and need intravenous antibiotics for fever. The enzyme is designed to break down antibiotics in the gut, protecting the natural bacteria there. Researchers will check safety, whether…
Phase: PHASE1, PHASE2 • Sponsor: Theriva Biologics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
Experimental cocktail aims to beat back tough leukemia
Disease control OngoingThis phase 2 trial tests a combination of chidamide, azacytidine, and a chemotherapy regimen (HAG) in 21 adults with acute myeloid leukemia that has come back or not responded to treatment. The goal is to see how well the combo works and what side effects it causes. Participants …
Phase: PHASE2 • Sponsor: The First Affiliated Hospital of Soochow University • Aim: Disease control
Last updated Jun 27, 2026 11:03 UTC
-
New hope for blood cancer patients: using mismatched donors for transplants
Disease control OngoingThis study tests a stem cell transplant using donors who are not a perfect match for patients with blood cancers like leukemia and lymphoma. Doctors give special drugs after the transplant to help prevent the donor cells from attacking the patient's body. The goal is to see if th…
Phase: PHASE2 • Sponsor: Center for International Blood and Marrow Transplant Research • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New immune cell therapy targets Hard-to-Treat cancers
Disease control OngoingThis early-phase trial tests a new type of immune cell therapy called NW-301VT for people with advanced solid tumors that have a specific KRAS mutation (G12V) and no standard treatment options. The therapy uses the patient's own T cells, which are genetically engineered to recogn…
Phase: PHASE1 • Sponsor: Zhejiang University • Aim: Disease control
Last updated Jun 27, 2026 11:02 UTC
-
New hope for AML patients: oral drug aims to keep remission going
Disease control OngoingThis study looks at how well and how safely oral azacitidine (ONUREG) works as maintenance therapy for Chinese adults with acute myeloid leukemia (AML) who are in remission after initial chemotherapy. The 44 participants cannot or choose not to have a stem cell transplant. Resear…
Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug HRS-6209 tested in advanced cancer patients
Disease control OngoingThis early-phase study tests a new drug called HRS-6209 in about 56 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. Participants will receive the…
Phase: PHASE1 • Sponsor: Jiangsu HengRui Medicine Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Two-Antibody combo takes on advanced cancers
Disease control OngoingThis study is testing a new combination of two drugs (AK112 and AK117) in about 154 adults with advanced solid tumors that have not responded to standard treatments. The goal is to see if the combination can shrink tumors and how safe it is. Participants receive the drugs intrave…
Phase: PHASE1, PHASE2 • Sponsor: Akeso • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug combo targets Hard-to-Treat cancers in early trial
Disease control OngoingThis Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…
Phase: PHASE1 • Sponsor: Institute of Cancer Research, United Kingdom • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
New drug IBI363 aims to supercharge immune system against tough cancers
Disease control OngoingThis early-phase trial tests IBI363, a drug designed to both stimulate immune cells and block a cancer defense, in about 40 adults with advanced solid tumors or lymphomas that have not responded to standard treatments. The main goal is to find a safe dose and check for side effec…
Phase: PHASE1 • Sponsor: Innovent Biologics (Suzhou) Co. Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New drug combo aims to wipe out leukemia cells in High-Risk patients
Disease control OngoingThis phase 2 trial tests whether adding daratumumab, an antibody that targets a protein on leukemia cells, to standard chemotherapy can clear all signs of cancer in adults with very high-risk T-cell acute lymphoblastic leukemia (T-ALL). About 31 patients aged 18-65 will receive t…
Phase: PHASE2 • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
New targeted therapy shows promise for Hard-to-Treat cancers
Disease control OngoingThis study tests a new drug called brenetafusp for adults with advanced solid tumors that have a specific marker (PRAME) and tissue type (HLA-A*02:01). The drug is designed to help the immune system find and attack cancer cells. The goal is to check if it is safe and if it can sh…
Phase: PHASE1, PHASE2 • Sponsor: Immunocore Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New liposomal drug shows promise for Hard-to-Treat cancers
Disease control OngoingThis early-stage study tests a new drug called E7389 liposomal formulation in people with advanced solid tumors that have not responded to standard treatments. The main goal is to find the safest dose and check for side effects. The study also looks at how the drug works in speci…
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
New drug E7386 tested for tough cancers
Disease control OngoingThis early-phase study tests a new drug called E7386 in about 70 people with advanced solid tumors, including colorectal cancer. The main goal is to check safety and find the right dose. Participants have tumors that no longer respond to standard treatments.
Phase: PHASE1 • Sponsor: Eisai Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New drug combo shows promise for rare childhood leukemia
Disease control OngoingThis study tests whether adding a drug called selinexor to standard chemotherapy can help children with a specific, high-risk form of acute myeloid leukemia (NUP98-positive AML). Ten children will receive the combination during their first two rounds of treatment. The goal is to …
Phase: PHASE2 • Sponsor: The Children's Hospital of Zhejiang University School of Medicine • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
New hope for Hard-to-Treat blood cancers? early trial targets genetic weakness
Disease control OngoingThis early-phase study tests whether the drug talazoparib can help people with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) who have a specific genetic mutation (cohesin) and cannot receive standard intensive chemotherapy. The main goal is to see if the drug red…
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:08 UTC
-
Blood cancer transplant trial using banked donor marrow pulled before start
Disease control TerminatedThis Phase 1 trial aimed to test whether bone marrow from deceased, mismatched unrelated donors could be safely used for transplants in patients with blood cancers like leukemia. The approach used stored (cryopreserved) marrow along with drugs to prevent rejection. However, the s…
Phase: PHASE1 • Sponsor: Ossium Health, Inc. • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New pill shows promise against lung cancer in early trial
Disease control OngoingThis study tests an oral drug called TAK-788 (mobocertinib) in adults with advanced non-small cell lung cancer. The goal is to find the best dose, check safety, and see if the drug shrinks tumors. Participants take TAK-788 capsules, sometimes with chemotherapy, and continue treat…
Phase: PHASE1, PHASE2 • Sponsor: Takeda • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New immune drug shows promise in early trial for Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …
Phase: PHASE1, PHASE2 • Sponsor: Ascendis Pharma Oncology Division A/S • Aim: Disease control
Last updated Jun 27, 2026 09:07 UTC
-
New combo therapy targets genetic weakness in Hard-to-Treat leukemia
Disease control OngoingThis study tests two experimental drugs (AG-120 and AG-221) that target specific genetic mutations (IDH1 or IDH2) found in some acute myeloid leukemia (AML) patients. Each drug is combined with a standard chemotherapy (azacitidine) and compared to azacitidine alone. The trial enr…
Phase: PHASE1, PHASE2 • Sponsor: Celgene • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Arsenic and vitamin a derivative may replace harsh chemo for leukemia
Disease control OngoingThis phase III trial tests a combination of arsenic trioxide and tretinoin (a vitamin A derivative) in 158 people with newly diagnosed acute promyelocytic leukemia (APL). The goal is to see if this drug pair can replace high-dose anthracycline chemotherapy, which can cause long-t…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
Fitness test could guide safer stem cell transplants for seniors
Disease control OngoingThis study tests whether a geriatric assessment—looking at thinking, mobility, mood, nutrition, and medications—can help doctors choose the right transplant intensity for patients aged 60 and older with myeloid blood cancers. The goal is to reduce deaths from transplant complicat…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New radiation combo aims to make stem cell transplants safer for leukemia patients
Disease control TerminatedThis early-phase trial tests a precise radiation technique called total marrow/lymphoid irradiation (TMLI) combined with the chemotherapy drug cyclophosphamide for people with acute myeloid leukemia in remission. The goal is to see if this approach is safe and can help prepare th…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New combo therapy aims to improve stem cell transplants for leukemia patients
Disease control OngoingThis study tests a new conditioning regimen using a precise type of radiation (helical tomotherapy) along with two chemotherapy drugs (fludarabine and melphalan) before a donor stem cell transplant. The goal is to reduce side effects and improve outcomes for people with leukemia …
Phase: PHASE1, PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug cocktail aims to shrink Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…
Phase: PHASE1, PHASE2 • Sponsor: AstraZeneca • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cancer combo aims to supercharge immune attack on tumors
Disease control OngoingThis early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…
Phase: PHASE1 • Sponsor: Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Smart immune cells take aim at tough blood cancers
Disease control OngoingThis early-stage trial tests a new therapy called SENTI-202, which uses specially designed immune cells (CAR NK cells) to find and attack cancer cells in people with certain blood cancers like acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The cells are 'off-the…
Phase: PHASE1 • Sponsor: Senti Biosciences • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
Experimental cell combo takes on advanced cancers in early trial
Disease control OngoingThis early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…
Phase: PHASE1 • Sponsor: Tianjin Medical University Cancer Institute and Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New pill aims to keep AML in remission for older japanese patients
Disease control OngoingThis study tests whether taking an oral chemotherapy drug (azacitidine) as maintenance therapy can help keep acute myeloid leukemia (AML) from returning in Japanese patients aged 55 and older who are already in remission. Participants will receive either the drug or a placebo, al…
Phase: PHASE2 • Sponsor: Bristol-Myers Squibb • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
Promising blood cancer combo trial pulled before it even started
Disease control TerminatedThis early-stage trial aimed to test a combination of two drugs—ASTX727 (already approved for some blood cancers) and ASTX029 (an experimental ERK inhibitor)—in adults with myelodysplastic syndromes (MDS) or related blood cancers that have a mutation in the RAS pathway. The goal …
Phase: PHASE1, PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:04 UTC
-
New drug ST101 takes on Hard-to-Treat cancers
Disease control OngoingThis study tests an experimental drug called ST101 in people with advanced solid tumors that cannot be removed by surgery or have spread. The trial includes cancers like glioblastoma, melanoma, breast, and prostate cancer. It aims to find a safe dose and see if the drug can shrin…
Phase: PHASE1, PHASE2 • Sponsor: Sapience Therapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
Hitchhiking drug targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage trial tests a new drug called SON-1010 in 42 adults with advanced solid tumors that have spread or cannot be removed. The drug is designed to hitch a ride on a blood protein called albumin to deliver an immune-boosting signal (IL-12) directly to the tumor area. T…
Phase: PHASE1 • Sponsor: Sonnet BioTherapeutics • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Immune cell therapy aimed at autoimmune diseases hits early snag
Disease control TerminatedThis early-phase trial planned to test a one-time infusion of genetically modified immune cells (CAR-T cells) targeting CD19 in people with several autoimmune diseases, including lupus and multiple sclerosis. The goal was to see if it was safe and could reduce harmful antibodies.…
Phase: EARLY_PHASE1 • Sponsor: Nanjing Bioheng Biotech Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Can a lower dose of this leukemia drug keep the disease at bay?
Disease control ENROLLING_BY_INVITATIONThis study looks at whether reducing the dose of the drug olverembatinib can still control chronic myeloid leukemia in patients who have already responded well to treatment. About 100 adults with chronic or accelerated phase CML will switch to a lower dose (20 mg every other day)…
Sponsor: Qian Jiang • Aim: Disease control
Last updated Jun 27, 2026 09:01 UTC
-
Precision radiation may make stem cell transplants safer for leukemia patients
Disease control OngoingThis study tests a new way to deliver radiation before a stem cell transplant for people with leukemia or myelodysplastic syndrome. Instead of radiating the whole body, the new method targets only the bone marrow and lymph nodes, which may reduce damage to healthy organs. The goa…
Phase: PHASE2 • Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New Triple-Drug cocktail targets tough blood cancers
Disease control OngoingThis early-phase study tests the safety of combining three drugs—navitoclax, venetoclax, and decitabine—for people with advanced myeloid blood cancers like leukemia and myelofibrosis. The goal is to find a safe dose that can control the disease. Sixteen adults aged 18 and older a…
Phase: PHASE1 • Sponsor: Jacqueline Garcia, MD • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New strategy aims to tame common virus after stem cell transplants
Disease control OngoingThis study tests a modified plan to prevent and treat cytomegalovirus (CMV) infection in people with blood cancers who have had a donor stem cell transplant. CMV is a common virus that can cause serious problems after transplant. The study involves 153 participants and looks at w…
Sponsor: City of Hope Medical Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug cocktail may tame deadly transplant complication
Disease control OngoingThis study tests a new combination of three drugs (cyclophosphamide, abatacept, and tacrolimus) given at lower doses to prevent graft-versus-host disease (GVHD) in 27 adults receiving a stem cell transplant from a half-matched donor. GVHD is a serious condition where donor cells …
Phase: PHASE2 • Sponsor: NYU Langone Health • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
Could a cancer drug shield young transplant patients from a deadly complication?
Disease control OngoingThis study tests whether adding the drug vorinostat to standard care can prevent graft-versus-host disease (GVHD) in children, adolescents, and young adults receiving a bone marrow or blood stem cell transplant for blood cancers. Researchers are first finding the best dose of vor…
Phase: PHASE1, PHASE2 • Sponsor: University of Michigan Rogel Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug combo shows promise in early trial for tough blood cancer
Disease control OngoingThis early-phase study tests whether combining two drugs, venetoclax and inotuzumab ozogamicin, is safe and effective for people with B-cell acute lymphoblastic leukemia (B-ALL), a fast-growing blood cancer. About 23 adults whose cancer has returned or not responded to treatment …
Phase: PHASE1 • Sponsor: Dana-Farber Cancer Institute • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New drug candidate targets Hard-to-Treat cancers in early trial
Disease control OngoingThis early-stage study tests an experimental drug called FDA018-ADC in about 78 adults with advanced solid tumors (like breast, lung, or bladder cancer) who have run out of standard options. The main goals are to find a safe dose and check for side effects, while also seeing if t…
Phase: PHASE1 • Sponsor: Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New drug SH006 tested in patients with advanced solid tumors
Disease control OngoingThis early-stage trial tests the safety and tolerability of a new drug called SH006 in 50 adults with advanced solid tumors, including liver cancer. Participants receive SH006 every three weeks. The study aims to find the best dose for future trials and monitor side effects. It i…
Phase: PHASE1 • Sponsor: Nanjing Sanhome Pharmaceutical, Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New Antibody-Drug conjugate takes aim at tough leukemias
Disease control OngoingThis first-in-human trial tests BYON4413, an antibody-drug conjugate designed to target and kill cancer cells in people with relapsed or refractory acute myeloid leukemia (AML) or myelodysplastic neoplasms (MDS). The study involves 16 participants and aims to check safety, how th…
Phase: PHASE1 • Sponsor: Byondis B.V. • Aim: Disease control
Last updated Jun 27, 2026 08:13 UTC
-
New cell therapy aims to boost cancer fight
Disease control OngoingThis early-stage study tests a new treatment called ACIT-1, which uses donated immune cells to help fight cancer. About 34 adults with pancreatic or other cancers will receive one of four doses to find the safest and most effective dose. The goal is to see if the therapy can safe…
Phase: PHASE1, PHASE2 • Sponsor: Cancer Vaccines Limited • Aim: Disease control
Last updated Jun 27, 2026 08:12 UTC
-
New hope for Hard-to-Treat cancers: NUV-1511 enters human trials
Disease control OngoingThis study tests a new drug, NUV-1511, in people with advanced solid tumors that have not responded to other treatments. The goal is to find safe doses and see if the drug can shrink tumors in cancers like breast, prostate, pancreatic, and ovarian cancer. About 466 adults will ta…
Phase: PHASE1, PHASE2 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Compassionate use study offers AML patients continued access to experimental oral chemo
Disease control OngoingThis study gives a small group of adults with acute myeloid leukemia (AML) continued access to an oral form of the chemotherapy drug azacitidine after they finished a previous trial. The main goal is to track any side effects and see how safe the drug is over a longer period. Abo…
Phase: NA • Sponsor: Hikma Pharmaceuticals LLC • Aim: Disease control
Last updated Jun 27, 2026 08:11 UTC
-
Radiation boost may help stem cell transplants beat tough leukemia
Disease control OngoingThis phase II trial tests whether adding targeted total marrow irradiation to standard chemotherapy before a stem cell transplant can help prevent relapse in people with high-risk acute myeloid leukemia or myelodysplastic syndromes. About 38 adults aged 18–65 will receive the com…
Phase: PHASE2 • Sponsor: University of Illinois at Chicago • Aim: Disease control
Last updated Jun 27, 2026 08:10 UTC
-
AI that reads faces could spot hidden distress in cancer patients
Diagnosis ENROLLING_BY_INVITATIONThis trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…
Sponsor: Chinese PLA General Hospital • Aim: Diagnosis
Last updated Aug 16, 2026 00:00 UTC
-
Can a new PET tracer reveal hidden immune clues in tumors?
Diagnosis TerminatedThis phase I trial tests an experimental imaging agent called 64Cu-DOTA-pembrolizumab, which is designed to attach to PD1, a protein on immune cells that often cluster around tumors. By injecting this agent and then performing a PET scan, researchers hope to see where these immun…
Phase: PHASE1 • Sponsor: City of Hope Medical Center • Aim: Diagnosis
Last updated Aug 14, 2026 00:00 UTC
-
Can a new tracer light up cancer growth?
Diagnosis OngoingThis trial is testing a new imaging tracer called FLT, which is used with a PET scan to measure how fast tumors are growing. The study includes people with various cancers or those awaiting a biopsy for a suspicious mass. The goal is to see if FLT PET imaging can help find and di…
Sponsor: Barbara Ann Karmanos Cancer Institute • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new PET tracer spot tumors more clearly?
Diagnosis TerminatedThis trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…
Sponsor: Jinling Hospital, China • Aim: Diagnosis
Last updated Aug 12, 2026 00:00 UTC
-
Can a new tracer light up tumors better than standard PET scans?
Diagnosis ENROLLING_BY_INVITATIONThis trial is testing an experimental imaging agent called [68Ga]Ga-ELI411, which is designed to bind to a protein (FAP) found in many solid tumors. The study will involve 18 adults with confirmed solid tumors who are already scheduled for a standard FDG-PET scan. Participants wi…
Phase: EARLY_PHASE1 • Sponsor: Union Hospital, Tongji Medical College, Huazhong University of Science and Technology • Aim: Diagnosis
Last updated Aug 05, 2026 00:00 UTC
-
Finger-Prick test could replace needles for cancer blood monitoring
Diagnosis TerminatedThis study tests a new device that measures blood counts from a tiny finger-prick sample in cancer patients. Researchers will compare these results to standard lab tests from regular blood draws. The goal is to see if the device is accurate enough to eventually allow patients to …
Sponsor: Entia Ltd • Aim: Diagnosis
Last updated Jul 31, 2026 00:00 UTC
-
Can a simple ultrasound predict immunotherapy success?
Diagnosis TerminatedThis study explores whether special ultrasound techniques can detect early signs that cancer immunotherapy is working. Researchers will scan tumors in 30 adults with solid tumors before and after three weeks of treatment. The goal is to see if changes in blood flow measured by ul…
Phase: NA • Sponsor: Stanford University • Aim: Diagnosis
Last updated Jun 27, 2026 12:29 UTC
-
Could a routine blood test spot many cancers early?
Diagnosis OngoingThis study aims to create a screening tool that uses common blood test results to detect various cancers early. Researchers will analyze data from 10 million cancer patients and healthy individuals, using machine learning to find patterns. The goal is a low-cost, non-invasive tes…
Sponsor: Zhejiang Cancer Hospital • Aim: Diagnosis
Last updated Jun 27, 2026 12:24 UTC
-
Hidden heart risk in cancer patients: simple ECG screening could save lives
Diagnosis OngoingThis study tests whether a simple 30-second ECG using a handheld device can find undiagnosed atrial fibrillation (an irregular heartbeat) in people aged 65 and older with cancer. About 500 participants will be randomly assigned to either get the quick screening or usual care. The…
Phase: NA • Sponsor: University of Oklahoma • Aim: Diagnosis
Last updated Jun 27, 2026 12:04 UTC
-
New PET scan agent could predict cancer therapy success, but trial never started
Diagnosis TerminatedThis pilot study aimed to test whether a radioactive imaging agent called 68Ga-FAPI-46 could predict how well solid tumor patients respond to antibody therapy. The plan was to give 50 participants an injection of the agent, then perform a PET/CT scan and compare it to standard MR…
Phase: EARLY_PHASE1 • Sponsor: Eben Rosenthal • Aim: Diagnosis
Last updated Jun 27, 2026 08:13 UTC
-
Probiotics may shield cancer patients from Immunotherapy's gut woes
Prevention TerminatedThis study tests whether taking an over-the-counter probiotic (VSL#3® 450B) can prevent colitis (colon inflammation) and diarrhea in cancer patients receiving immunotherapy. Up to 45% of patients on these drugs develop this side effect. The trial enrolls adults with solid tumors …
Phase: NA • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 27, 2026 08:13 UTC
-
Pen and paper: a new weapon against blood cancer stress?
Symptom relief OngoingThis study explores whether an online expressive writing workshop can boost mental wellness in young adults (ages 18-39) with blood cancer. One hundred participants will either start the workshop right away or wait four weeks. Everyone takes surveys about their mood and stress ov…
Phase: NA • Sponsor: Blood Cancer United • Aim: Symptom relief
Last updated Aug 15, 2026 00:00 UTC
-
Can a smartphone app help young cancer survivors get moving and improve their quality of life?
Symptom relief OngoingThis study tests a 12-week mobile health program for 304 young adult cancer survivors (ages 18-39) who finished treatment within the last 5 years. The program combines social support and mindfulness training to encourage moderate-to-vigorous physical activity. The goal is to see …
Phase: NA • Sponsor: Northwestern University • Aim: Symptom relief
Last updated Aug 14, 2026 00:00 UTC
-
New online program aims to ease pain for cancer survivors
Symptom relief OngoingThis study tests whether an internet-based pain coping skills program can help cancer survivors manage ongoing pain. About 456 adults who have completed cancer treatment or are on maintenance therapy will take part. Participants will either get the online program plus enhanced us…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Cancer breathlessness study: can opioids help you walk easier?
Symptom relief OngoingThis study tests if fast-acting opioids (fentanyl or morphine) can reduce shortness of breath during or after walking in 150 cancer patients who already take strong painkillers. Participants will take the drug or a placebo before a short walk test, and researchers will measure ch…
Phase: PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Can a sugar pill you know is fake fight cancer fatigue?
Symptom relief OngoingThis study tests whether an open labeled placebo—a pill with no active medicine that patients know is a placebo—can reduce fatigue in people with advanced cancer. About 100 participants will either receive the placebo or be placed on a waitlist. The goal is to see if simply takin…
Phase: PHASE2, PHASE3 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Aug 13, 2026 00:00 UTC
-
Virtual reality headsets may calm cancer patients before radiation
Symptom relief ENROLLING_BY_INVITATIONThis trial tests whether a virtual reality (VR) educational video can reduce anxiety and improve satisfaction in adults starting their first course of external beam radiotherapy for cancer. Half of the 122 participants will watch a VR video through a headset before treatment, whi…
Phase: NA • Sponsor: Oman Ministry of Health • Aim: Symptom relief
Last updated Aug 12, 2026 00:00 UTC
-
A digital bridge: could an online pathway ease depression in cancer care?
Symptom relief OngoingThis study tests an online pathway called iPath*D that guides cancer patients who report depression symptoms from screening to treatment options. The goal is to see if the tool is acceptable and easy to use for adults starting cancer treatment. Researchers will measure usability,…
Phase: NA • Sponsor: Dartmouth-Hitchcock Medical Center • Aim: Symptom relief
Last updated Aug 09, 2026 00:00 UTC
-
Mind over body: new film series aims to boost wellbeing in young cancer survivors
Symptom relief OngoingThis study tests a digital program called EMBody for cancer survivors aged 16-25 who finished treatment up to seven years ago. The program uses short films and reflection activities to help them develop a healthier mindset about their body. Researchers want to see if it improves …
Phase: NA • Sponsor: King's College London • Aim: Symptom relief
Last updated Aug 08, 2026 00:03 UTC
-
Veterans with cancer get help discussing End-of-Life wishes in group sessions
Symptom relief OngoingThis study tests whether group education sessions can help veterans with newly diagnosed cancer discuss their goals of care and complete advance directives. Fifty veterans will attend two virtual or in-person sessions led by a trained health educator. Researchers will check if th…
Phase: NA • Sponsor: VA Palo Alto Health Care System • Aim: Symptom relief
Last updated Aug 07, 2026 00:00 UTC
-
Can two existing drugs help cancer patients ditch steroids?
Symptom relief OngoingThis study tests whether rituximab or tocilizumab can help people with advanced cancer stop taking steroids for side effects caused by immunotherapy. About 8 participants will receive one of these drugs to see if they can safely reduce or stop steroid treatment within 4 weeks. Th…
Phase: PHASE2 • Sponsor: Columbia University • Aim: Symptom relief
Last updated Aug 05, 2026 00:00 UTC
-
Faith and mindfulness join forces to heal black cancer survivors
Symptom relief ENROLLING_BY_INVITATIONThis trial tests a mindfulness program that blends stress-reduction techniques with Christian principles to improve well-being in Black adult cancer survivors. Participants take part in a silent mindfulness retreat, focus groups, interviews, and questionnaires. The study measures…
Phase: NA • Sponsor: Mayo Clinic • Aim: Symptom relief
Last updated Jul 23, 2026 00:00 UTC
-
Can a calming drug combo bring clarity to cancer patients?
Symptom relief OngoingThis study looks at whether adding lorazepam to haloperidol can better reduce delirium (sudden confusion and agitation) in people with advanced cancer who are in a palliative care unit. About 93 participants will receive either haloperidol alone or with lorazepam, and their level…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 19, 2026 00:00 UTC
-
Can writing about cancer help young survivors heal?
Symptom relief OngoingThis study tests whether a virtual group writing program can improve quality of life for young adults who survived cancer. Thirty survivors aged 18-39, diagnosed 1-5 years ago, will write about their cancer experiences in a group setting. The goal is to see if this simple, access…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Virtual reality offers escape for bone marrow transplant patients
Symptom relief OngoingThis study tests whether using virtual reality (VR) can improve symptoms like pain, anxiety, and fatigue in patients receiving a bone marrow transplant. About 28 adults will be randomly assigned to either VR sessions or standard care during their hospital stay. The goal is to see…
Phase: NA • Sponsor: Roswell Park Cancer Institute • Aim: Symptom relief
Last updated Jul 18, 2026 00:00 UTC
-
Sniffing away sickness: essential oils tested for chemo nausea
Symptom relief TerminatedThis trial explores whether inhaling essential oils like peppermint, lavender, or ginger can help reduce nausea and anxiety in cancer patients receiving chemotherapy infusions. Current anti-nausea drugs often cause constipation and fatigue, so researchers are looking for gentler …
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jul 15, 2026 00:00 UTC
-
Testosterone gel trial aims to beat cancer fatigue in older men
Symptom relief OngoingThis study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…
Phase: PHASE2 • Sponsor: Seattle Institute for Biomedical and Clinical Research • Aim: Symptom relief
Last updated Jul 08, 2026 00:00 UTC
-
Could a single doctor visit reduce cancer distress?
Symptom relief ENROLLING_BY_INVITATIONThis study explores whether a structured survivorship care visit, conducted early in cancer treatment, can help reduce psychological distress and improve quality of life. Adults with any type of cancer who report significant distress will meet with a physician assistant to discus…
Phase: NA • Sponsor: Ellis Medicine • Aim: Symptom relief
Last updated Jul 01, 2026 00:00 UTC
-
Green tea extract tested to fight frailty in older cancer survivors
Symptom relief TerminatedThis phase 2 trial tests whether a daily dose of EGCG, a compound found in green tea, can reduce frailty and inflammation in people aged 65 and older who have survived cancer. About 118 participants will take either EGCG or a placebo for 12 weeks. The study is currently suspended…
Phase: PHASE2 • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 28, 2026 00:00 UTC
-
Could an herbal patch ease pain after cancer?
Symptom relief OngoingThis study tests whether an over-the-counter herbal pain patch, called Tibetree Pain Relieving Plaster, can reduce muscle and joint pain in people who have finished active cancer treatment. Sixty-eight cancer survivors will apply either the active patch or a placebo patch to thei…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 14:00 UTC
-
New support program aims to ease emotional burden of advanced cancer
Symptom relief ENROLLING_BY_INVITATIONThis pilot study tests a support program called CASA for people with advanced cancer and their caregivers. The program includes five counseling sessions to help with spiritual well-being and emotional distress. Researchers will enroll 124 participants to see if the program is hel…
Phase: NA • Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
Cancer survivors find hope in Peer-Led Self-Management program
Symptom relief OngoingThis study tests a 7-session, peer-led self-management program for 234 cancer survivors who recently finished treatment with curative intent. The program aims to reduce anxiety and depression by teaching symptom management skills in a group setting. Participants are from central …
Phase: NA • Sponsor: University of Aarhus • Aim: Symptom relief
Last updated Jun 27, 2026 13:08 UTC
-
New telehealth program aims to ease emotional burden of advanced cancer
Symptom relief ENROLLING_BY_INVITATIONThis study is testing a 5-session telehealth program called CASA that helps advanced cancer patients and their caregivers cope with emotional and spiritual challenges. The program is designed for people with stage III or IV cancer and their caregivers. The goal is to see if it im…
Phase: NA • Sponsor: Ponce Medical School Foundation, Inc. • Aim: Symptom relief
Last updated Jun 27, 2026 13:05 UTC
-
No more hospital trips? video nutrition counseling tested for cancer weight loss
Symptom relief OngoingThis study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…
Phase: NA • Sponsor: King Edward Medical University • Aim: Symptom relief
Last updated Jun 27, 2026 13:04 UTC
-
New study aims to tackle loneliness in cancer survivors
Symptom relief ENROLLING_BY_INVITATIONThis study tests a 9-week virtual program that helps cancer survivors build social connections and reduce loneliness. Participants work one-on-one with a facilitator to create a personalized action plan. The goal is to see if this approach improves well-being and quality of life.
Phase: NA • Sponsor: University of Washington • Aim: Symptom relief
Last updated Jun 27, 2026 13:02 UTC
-
Holy Qur'an or music: which helps kids on chemo sleep better?
Symptom relief OngoingThis study compares listening to Holy Qur'an recitation versus calming music before bed in children aged 6 to 10 who are undergoing chemotherapy. Sleep problems are common in these children, and the goal is to find a safe, non-medication way to improve sleep quality. Ninety child…
Phase: NA • Sponsor: Rawand Shafeeq Ali • Aim: Symptom relief
Last updated Jun 27, 2026 13:00 UTC
-
Talking hope: new therapy aims to lift spirits of cancer patients during radiation
Symptom relief ENROLLING_BY_INVITATIONThis study tests whether a special type of counseling called hope-focused motivational interviewing can improve hope, self-confidence, and self-compassion in cancer patients who are getting radiation therapy. About 46 adults with early-stage cancer will be randomly assigned to re…
Phase: NA • Sponsor: Saglik Bilimleri Universitesi • Aim: Symptom relief
Last updated Jun 27, 2026 12:34 UTC
-
Virtual reality could ease stress of bone marrow transplants
Symptom relief OngoingThis study tests whether a virtual reality (VR) program can help people undergoing bone marrow transplants cope with stress and improve their quality of life. About 80 adult patients with blood cancer will be randomly assigned to either receive the VR program plus usual care, or …
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:33 UTC
-
Can a virtual sleep program help cancer survivors beat insomnia?
Symptom relief OngoingThis study aims to find the best way to deliver cognitive behavioral therapy for insomnia (CBT-I) to cancer survivors who have chronic sleep problems. Researchers are comparing individual vs. group sessions and whether adding booster sessions helps. The goal is to create an effec…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:31 UTC
-
Could early comfort care change End-of-Life for blood cancer patients?
Symptom relief OngoingThis study looks at whether starting palliative care early can help adults with aggressive leukemias or myelodysplastic syndrome (MDS) have a better end-of-life experience. Researchers will compare where patients die (home, hospice, or hospital) and how often they need hospital c…
Phase: NA • Sponsor: University of Virginia • Aim: Symptom relief
Last updated Jun 27, 2026 12:29 UTC
-
Fitbit and app aim to boost activity in cancer survivors
Symptom relief OngoingThis study looks at whether personalized exercise plans delivered through a Fitbit and a smartphone app can help cancer survivors become more physically active. Researchers will track steps, weight, quality of life, and emotional well-being in 160 adult survivors who have finishe…
Phase: NA • Sponsor: The University of Tennessee, Knoxville • Aim: Symptom relief
Last updated Jun 27, 2026 12:28 UTC
-
New toolkit aims to boost recovery for older cancer surgery patients
Symptom relief OngoingThis study tests a pre-surgical toolkit (OPTI-Surg) designed to help older cancer patients recover more quickly after major surgery. The toolkit provides recommendations before surgery to improve physical function and reduce complications. About 325 participants with various canc…
Phase: NA • Sponsor: Alliance for Clinical Trials in Oncology • Aim: Symptom relief
Last updated Jun 27, 2026 12:26 UTC
-
Can an iPad program help older cancer patients stay strong?
Symptom relief OngoingThis study looks at whether an 8-week digital program called COBRA, which includes balance and resistance exercises, is safe and practical for older adults with cancer. The program is delivered via an iPad with video calls. Researchers will track how many participants stick with …
Phase: NA • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 12:23 UTC
-
Fitbit for cancer care: new study tests remote exercise monitoring
Symptom relief OngoingThis study looks at whether using activity trackers and a phone app can help people with cancer reach their exercise goals during treatment. Twenty-five participants will wear the trackers for three months. The goal is to see if this approach is practical and helpful for both pat…
Phase: NA • Sponsor: Shirley Ryan AbilityLab • Aim: Symptom relief
Last updated Jun 27, 2026 12:10 UTC
-
Can online yoga help cancer survivors sleep better?
Symptom relief OngoingThis study tests whether virtual yoga classes can help cancer survivors who have trouble sleeping. About 42 survivors will either take 8 virtual yoga sessions over 4 weeks or continue their usual care. Researchers will measure changes in insomnia and sleep quality to see if the o…
Phase: NA • Sponsor: University of Rochester • Aim: Symptom relief
Last updated Jun 27, 2026 12:08 UTC
-
Can yoga and relaxation help young cancer survivors? new study tests a Stress-Busting program
Symptom relief OngoingThis study tests a group program called the Relaxation Response Resiliency Program (3RP-AYA) for adolescents and young adults who finished cancer treatment in the last 5 years. The program uses mind-body techniques like imagery, relaxation, and yoga to reduce stress and build res…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Symptom relief
Last updated Jun 27, 2026 12:07 UTC
-
Smartphone app aims to ease suffering for advanced cancer patients
Symptom relief OngoingThis study tests whether a mobile app called SUPPORT+ can improve quality of life for adults with advanced cancer who are no longer receiving anticancer treatment. Participants use the app to report symptoms weekly, get self-care tips, and receive nurse follow-up if symptoms are …
Phase: NA • Sponsor: The University of Hong Kong • Aim: Symptom relief
Last updated Jun 27, 2026 12:03 UTC
-
Cash for cancer care: $1,000 a month trial aims to ease financial burden
Symptom relief OngoingThis study gives 250 advanced cancer patients $1,000 each month for a year to see if it reduces financial stress and improves quality of life. Participants also complete surveys every three months. The goal is to learn whether extra income can help patients stick to treatments an…
Phase: NA • Sponsor: Meredith Doherty, PhD, LCSW • Aim: Symptom relief
Last updated Jun 27, 2026 12:00 UTC
-
New meditation program aims to ease cancer symptoms in black patients
Symptom relief OngoingThis study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Can a smartphone app help rural cancer patients beat the odds?
Symptom relief OngoingThis study tests an electronic symptom management system called Nurse AMIE in 344 people with stage 3 or 4 cancer living in rural areas. The goal is to see if using the system helps them live longer and improves their quality of life. Participants use the system to report symptom…
Phase: NA • Sponsor: University of Pittsburgh • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Knee pain study for cancer patients pulled before starting
Symptom relief TerminatedThis study aimed to see if a special needle treatment (ultrasound-guided neuromodulation) could reduce front knee pain in cancer patients better than standard painkillers. It was planned for adults aged 18-65 with knee pain related to cancer. However, the study was withdrawn befo…
Phase: NA • Sponsor: Universidad Europea de Canarias • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Pain relief study for cancer patients withdrawn before starting
Symptom relief TerminatedThis trial was designed to see if nerve stimulation techniques could reduce lower limb pain in cancer patients better than medication. It was withdrawn before enrolling any participants, so no results are available. The study would have compared ultrasound-guided percutaneous neu…
Phase: NA • Sponsor: Universidad Europea de Canarias • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
Simple breathing trick may calm chemo nausea
Symptom relief OngoingThis study tests whether a relaxation breathing exercise can help reduce nausea and vomiting caused by chemotherapy in people with blood cancers. Sixty-eight patients are split into two groups: one does breathing exercises three times a day plus standard care, the other gets stan…
Phase: NA • Sponsor: Marmara University • Aim: Symptom relief
Last updated Jun 27, 2026 11:00 UTC
-
New combo treatment aims to quiet jaw pain for TMD sufferers
Symptom relief OngoingThis study tests whether wearing a custom mouth splint and getting a granisetron injection into the jaw muscle reduces pain from temporomandibular disorders (TMD) better than the splint alone or with lidocaine. About 48 adults with jaw muscle pain will be followed for 6 months. T…
Phase: PHASE4 • Sponsor: Mansoura University • Aim: Symptom relief
Last updated Jun 27, 2026 09:10 UTC
-
New online program aims to restore sexual health in young cancer survivors
Symptom relief OngoingThis study compares two brief online educational programs for young women (ages 19-49) who have finished cancer treatment and are dealing with sexual health issues. Participants join video sessions and report changes in sexual function and emotional well-being. The goal is to fin…
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Symptom relief
Last updated Jun 27, 2026 09:07 UTC
-
Could a simple referral to palliative care ease End-of-Life suffering for cancer patients?
Symptom relief OngoingThis study tests whether cancer patients who visit the emergency room for urgent problems benefit from being immediately referred to a palliative care team. The goal is to see if this reduces aggressive treatments and hospitalizations in the last month of life. The trial involves…
Phase: NA • Sponsor: Centre Leon Berard • Aim: Symptom relief
Last updated Jun 27, 2026 09:06 UTC
-
Music may soothe nerves during bone marrow biopsy
Symptom relief OngoingThis phase III trial tests whether listening to music during a bone marrow biopsy or aspiration can lower anxiety. About 113 adults with blood cancers will be randomly assigned to either receive standard care or also listen to music during the procedure. Researchers will measure …
Phase: PHASE3 • Sponsor: City of Hope Medical Center • Aim: Symptom relief
Last updated Jun 27, 2026 09:00 UTC
-
Exercise boosts quality of life in cancer patients, study finds
Symptom relief OngoingThis study looks at whether a supervised exercise program in community settings can improve quality of life and reduce fatigue in adults with cancer. 492 participants, including survivors and those on active treatment, will take part in group exercise sessions. Researchers will t…
Sponsor: University of Castilla-La Mancha • Aim: Symptom relief
Last updated Jun 27, 2026 08:14 UTC
-
Can acupuncture with electricity ease cancer brain fog and fatigue?
Symptom relief OngoingThis study tests whether electroacupuncture (a type of acupuncture with mild electrical pulses) can help cancer patients and survivors with clusters of symptoms like memory problems, fatigue, insomnia, anxiety, and depression. Seventy participants will receive either real electro…
Phase: NA • Sponsor: University of California, Irvine • Aim: Symptom relief
Last updated Jun 27, 2026 08:13 UTC
-
500 cancer Patients' records reviewed to tame immunotherapy side effects
Knowledge-focused OngoingThis study looks back at the medical records of 500 children and adults with cancer who received immunotherapy at the National Cancer Institute. The goal is to understand the side effects, like inflammation and immune reactions, that can happen with these treatments. By learning …
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Researchers dig into past data to uncover M7824's hidden side effects
Knowledge-focused OngoingThis study reviews medical records from 232 adults with cancer who received the immunotherapy drug M7824. The goal is to create a complete list of side effects caused by the drug. By understanding these risks, doctors hope to prevent or reduce them in future cancer treatments.
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Cancer drug interaction study: will antibiotics change how cediranib works?
Knowledge-focused OngoingThis Phase 1 study looks at how the antibiotic rifampicin changes the way the body processes the experimental cancer drug cediranib in 64 patients with advanced solid tumors. Participants take cediranib alone, then with rifampicin, then alone again to compare drug levels and safe…
Phase: PHASE1 • Sponsor: AstraZeneca • Aim: Knowledge-focused
Last updated Aug 18, 2026 03:00 UTC
-
Why are transplant survivors at higher heart risk? new study seeks answers
Knowledge-focused OngoingThis study looks at how well the heart, lungs, and muscles work together in people who have had a stem cell transplant. Researchers want to find out why transplant survivors have a higher risk of heart disease. About 350 adults with blood cancers will be followed for two years af…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Digital tools aim to close learning gaps for young cancer survivors
Knowledge-focused OngoingThis study tests whether a special website and video coaching for parents can help children aged 6-12 who had leukemia or lymphoma improve their learning and school performance. Many children survive these cancers but may struggle with memory, attention, and thinking due to treat…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Could muscle loss predict blood cancer outcomes?
Knowledge-focused OngoingThis study is investigating how common muscle loss, known as sarcopenia, is in people with blood cancers like leukemia, lymphoma, and myeloma. Researchers will measure body composition using DXA scans and track hospital stays, disease progression, and survival. The goal is to see…
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
Can cancer patients get better care at home? MD anderson investigates
Knowledge-focused TerminatedThis study aims to understand the experiences of cancer patients who receive care at home through MD Anderson's Care and Monitoring at Home program. Researchers will use surveys to measure quality of life and gather feedback from up to 40 participants. The goal is to learn whethe…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 16, 2026 00:00 UTC
-
A simple screening program could transform cancer aftercare
Knowledge-focused OngoingThis trial tests whether a structured, nurse-led symptom screening program can increase the number of cancer survivors who are screened for distress and referred to supportive services. The program includes nurse training and regular feedback, and it will be rolled out across mul…
Phase: NA • Sponsor: The University of Hong Kong • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
Massive study aims to uncover hidden triggers of blood cancers
Knowledge-focused ENROLLING_BY_INVITATIONThis study is collecting blood, bone marrow, and tissue samples from 5,000 people with blood cancers like leukemia and lymphoma. Researchers will analyze the samples to find genetic abnormalities that cause cancer cells to grow. The goal is to understand why these cancers develop…
Sponsor: OHSU Knight Cancer Institute • Aim: Knowledge-focused
Last updated Aug 15, 2026 00:00 UTC
-
New tool lets young cancer patients speak up about symptoms
Knowledge-focused OngoingThis study tests whether a simple questionnaire, filled out by children and teens with cancer (and their caregivers) before and after a clinic visit, can help doctors better understand their symptoms. About 85 participants will use the tool during routine visits. The goal is to s…
Phase: NA • Sponsor: Stanford University • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
Hidden risk: could opioid misuse be overlooked in cancer care?
Knowledge-focused TerminatedThis study aims to find out how often cancer patients treated with opioids for pain are at risk of misusing these medications. Researchers will use two screening questionnaires to assess misuse risk in 200 adult outpatients receiving opioids for cancer-related pain. The findings …
Sponsor: Rigshospitalet, Denmark • Aim: Knowledge-focused
Last updated Aug 14, 2026 00:00 UTC
-
15-Year safety watch for cell therapy recipients
Knowledge-focused ENROLLING_BY_INVITATIONThis study tracks the long-term safety of people who have already received a type of cell therapy called ADP adoptive cell therapy. Researchers will monitor up to 250 participants for up to 15 years after their last treatment to see if any delayed side effects occur. The goal is …
Phase: PHASE1 • Sponsor: USWM CT, LLC • Aim: Knowledge-focused
Last updated Aug 13, 2026 00:00 UTC
-
Gut bacteria may hold key to safer cancer immunotherapy
Knowledge-focused OngoingThis study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Aug 12, 2026 00:00 UTC
-
New study aims to perfect chemo dosing for cancer patients
Knowledge-focused OngoingThis study looks at whether a dye called iohexol can help doctors better calculate the dose of the chemotherapy drug carboplatin for cancer patients. The goal is to make sure patients get the right amount of drug to fight their cancer while reducing side effects. About 318 men wi…
Phase: PHASE1 • Sponsor: NRG Oncology • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
NIH launches massive sample collection to unlock disease secrets
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects blood, bone marrow, urine, and tissue samples from up to 6,000 people with solid tumors, blood cancers, or non-cancerous blood disorders, as well as from their healthy family members who are stem cell donors. The samples are stored and used in research to bett…
Sponsor: National Heart, Lung, and Blood Institute (NHLBI) • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
Heart safety check for new myelofibrosis drug in healthy volunteers
Knowledge-focused OngoingThis study evaluates whether a single dose of TQ05105, a JAK inhibitor being developed for myelofibrosis, affects the heart's electrical activity (QT interval) in healthy Chinese adults. Sixty participants receive TQ05105, placebo, and moxifloxacin (a positive control) in a cross…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Aug 09, 2026 00:00 UTC
-
New brain scan may predict chemo brain in young leukemia patients
Knowledge-focused TerminatedThis study tests a quick, non-invasive brain scan called Magnetic Resonance Fingerprinting (MRF) in children and young adults with acute leukemia. The goal is to see if the scan can detect early brain changes caused by chemotherapy. Participants also take a fun, game-like memory …
Phase: NA • Sponsor: Case Comprehensive Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Cancer tissue bank study aims to unlock new treatment clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study collects tissue and blood samples from 1,200 adults with known or suspected cancer. The samples are taken during standard surgeries or biopsies, with no extra procedures. Researchers will compare cancerous and normal tissues to identify differences that could lead to n…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Can a smartphone app get young cancer survivors moving? new study aims to find out.
Knowledge-focused OngoingThis study looks at whether a mobile health program combined with social media can help teens and young adults who survived childhood cancer become more physically active. About 387 participants will either use the program plus a fitness tracker or just the tracker alone. The goa…
Phase: PHASE3 • Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New study reveals hidden toll of Cancer-Related weight loss on families
Knowledge-focused OngoingThis study looks at how often cancer patients experience cachexia (unintentional weight loss and appetite loss) and how this affects both patients and their primary caregivers emotionally. About 192 patients and their caregivers will fill out questionnaires during supportive care…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Lab-Grown 3D tumors could help pick the right chemo for blood cancer patients
Knowledge-focused OngoingThis study uses bone marrow samples from 70 people with blood cancers to create 3D organoids—tiny lab-grown models that mimic the tumor's environment. Researchers will test different chemotherapy combinations on these organoids to see which kills the most cancer cells. The goal i…
Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
New testing method may guide targeted treatments for young leukemia patients
Knowledge-focused OngoingThis study looks at whether a special type of testing, called leukemia profiling, can help find personalized treatment options for children and young adults up to age 30 with recurrent, refractory, or high-risk leukemias. Researchers analyze the genetic changes in each patient's …
Phase: NA • Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Aug 08, 2026 00:03 UTC
-
Do blood thinners help or hurt when cancer meets a clot?
Knowledge-focused OngoingThis study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…
Sponsor: Children's Hospital Medical Center, Cincinnati • Aim: Knowledge-focused
Last updated Aug 07, 2026 00:00 UTC
-
Can natural remedies and cancer treatments mix safely? a new study investigates
Knowledge-focused OngoingThis study looks at how cancer patients use complementary and alternative medicine (CAM), such as herbal products and aromatherapy. Researchers will survey 500 patients and hold focus groups with 30-60 survivors to understand their needs, information sources, and any potential sa…
Phase: NA • Sponsor: Jules Bordet Institute • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Cancer patients with COVID-19: new study tracks their journey
Knowledge-focused OngoingThis study follows nearly 1,900 cancer patients who tested positive for COVID-19. Researchers collect blood samples, medical records, and images to see how the virus impacts their cancer treatment and overall health. The goal is to learn which factors make COVID-19 more severe in…
Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Aug 06, 2026 00:00 UTC
-
Chatbot could help families of kids with cancer understand genetic risks
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing whether a chatbot can help parents of children with cancer learn about genetic risks and decide whether to get tested themselves. The chatbot provides education and support as an alternative to speaking with a genetic counselor. The goal is to make it easier…
Phase: NA • Sponsor: Abramson Cancer Center at Penn Medicine • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Can a Finger-Prick replace the lab draw? a device puts accuracy to the test
Knowledge-focused TerminatedThis study is testing whether a new device called Liberty can accurately measure blood counts from a finger-prick sample compared to standard venous blood draws. Researchers will collect paired capillary and venous blood samples from healthy volunteers and cancer patients receivi…
Sponsor: Entia Ltd • Aim: Knowledge-focused
Last updated Jul 31, 2026 00:00 UTC
-
Could a COVID-19 shot boost cancer immunotherapy? a massive study digs into the timing.
Knowledge-focused OngoingThis large observational study looks at whether getting an mRNA COVID-19 vaccine shortly before or after starting immune checkpoint inhibitor therapy is linked to longer survival in adults with cancer. Using data from nearly 100,000 patients in France, researchers are comparing t…
Sponsor: Groupe Hospitalier Pitie-Salpetriere • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Gene test could personalize cancer drug dosing
Knowledge-focused OngoingThis study looks at whether a broad genetic test (microarray PGx) can find more drug-gene interactions than the standard single-gene test in 120 adults with cancer who are about to receive chemotherapy. The goal is to see if this extra information could help doctors adjust drug d…
Phase: NA • Sponsor: Wake Forest University Health Sciences • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
Stomach acid pill may change how new myelofibrosis drug works
Knowledge-focused OngoingThis early-stage study in 16 healthy adults checks if taking a common stomach acid drug (rabeprazole) changes how the body absorbs a new experimental drug (TQ05105) being developed for myelofibrosis. Participants take TQ05105 alone and later with rabeprazole to compare drug level…
Phase: PHASE1 • Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. • Aim: Knowledge-focused
Last updated Jul 29, 2026 00:00 UTC
-
New DNA test aims to predict bloodstream infections in kids with cancer
Knowledge-focused OngoingThis study at St. Jude Children's Research Hospital is testing whether a next-generation DNA test can predict bloodstream infections in children and teens with cancer who are at high risk. Current methods often detect infections too late, leading to severe illness or death. The g…
Sponsor: St. Jude Children's Research Hospital • Aim: Knowledge-focused
Last updated Jul 22, 2026 00:00 UTC
-
Can a simple sheet of paper improve cancer care conversations?
Knowledge-focused OngoingThis study compares two different information sheets given to advanced cancer patients and their caregivers before a doctor visit. One sheet has sample questions to ask, the other has general information. The goal is to see which one helps patients and caregivers communicate bett…
Phase: NA • Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Cancer Patients' pandemic struggles revealed in new study
Knowledge-focused OngoingThis study looks at how the COVID-19 pandemic impacted the well-being and quality of life of over 13,000 cancer patients and survivors. Researchers used questionnaires to gather information on experiences like exposure, isolation, and financial disruptions. The goal is to underst…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Artificial intelligence reads tissue samples in minutes to guide cancer surgery
Knowledge-focused OngoingThis study is developing an artificial intelligence model that can analyze frozen-section pathology images—tissue samples examined during surgery. The goal is to help pathologists quickly and accurately diagnose cancer while the patient is still in the operating room. Researchers…
Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University • Aim: Knowledge-focused
Last updated Jul 18, 2026 00:00 UTC
-
Island hopping for cancer care: first study maps Survivors' journeys across six caribbean nations
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 900 cancer survivors from six small island nations (Antigua, Dominica, Grenada, Saint Kitts, Saint Lucia, and Saint Vincent) to understand how traveling overseas for cancer treatment affects their health and social support. Researchers will compare those who se…
Sponsor: Vaughan A. Lewis Institute for Research and Innovation • Aim: Knowledge-focused
Last updated Jul 12, 2026 00:00 UTC
-
Pharmacist-Led lessons may cut infection risk in chemo patients
Knowledge-focused OngoingThis trial tests whether a pharmacist-led educational program helps cancer patients on high-risk chemotherapy better understand and follow neutropenic precautions—steps to prevent serious infections when white blood cell counts are low. About 300 adults with various cancers will …
Phase: NA • Sponsor: Jordan University of Science and Technology • Aim: Knowledge-focused
Last updated Jul 10, 2026 00:00 UTC
-
Could your workout history affect your Cancer's genes?
Knowledge-focused OngoingThis study creates a registry of cancer patients who have had their tumor genes analyzed. Participants fill out a 10-minute survey about their exercise habits before and after diagnosis. Researchers will look for connections between physical activity and genetic changes in tumors…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jul 08, 2026 00:00 UTC
-
Spirituality may be key to coping with blood cancer from day one
Knowledge-focused TerminatedThis study looks at how spirituality — personal beliefs, values, and meaning — influences adults recently diagnosed with blood cancers like lymphoma or leukemia, as well as their loved ones. Participants fill out three questionnaires about spiritual well-being, quality of life, a…
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jul 01, 2026 00:00 UTC
-
Can coaching caregivers improve cancer Decision-Making?
Knowledge-focused OngoingThis study tests a training program called CASCADE for family caregivers of people with advanced cancer. The goal is to see which parts of the training best help caregivers support patients in making medical decisions. 256 caregivers are taking part in different combinations of c…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a simple card keep cancer patients safer?
Knowledge-focused OngoingThis study tests whether giving cancer patients a drug vigilance card helps them avoid medication errors and interactions when seeing other doctors. One hundred patients on oral chemotherapy or targeted therapies at Limoges University Hospital will use the card. Researchers will …
Sponsor: University Hospital, Limoges • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a smart patch predict dangerous immune reactions in cancer treatment?
Knowledge-focused ENROLLING_BY_INVITATIONThis study tests whether a wearable patch called TempTraq can detect fevers earlier than standard temperature checks in cancer patients receiving immunotherapy. The goal is to see if continuous monitoring reduces the risk of severe cytokine release syndrome (CRS), a serious side …
Phase: NA • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:02 UTC
-
Do blood transfusions help at the end of life? a study asks patients and staff
Knowledge-focused OngoingThis study looks at how patients with advanced blood cancers (like acute myeloid leukemia) who are not eligible for a cure, along with their nurses and doctors, feel about the benefits of blood transfusions. Researchers will give questionnaires before each transfusion to compare …
Sponsor: University Hospital, Montpellier • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:01 UTC
-
New platform aims to personalize cancer treatment for GI patients
Knowledge-focused OngoingThis study aims to create a comprehensive precision oncology platform at the Chinese University of Hong Kong to personalize drug therapy for 170 patients with advanced gastrointestinal cancers. Researchers will collect tumor samples for genetic sequencing and grow patient-derived…
Sponsor: Brigette Ma • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Blood test may predict ICU death risk for cancer patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study examines whether a routine blood test called Mean Platelet Volume (MPV), taken when a cancer patient is admitted to the intensive care unit (ICU), can help predict their risk of dying. Researchers will review the medical records of 425 adult cancer patients who stayed …
Sponsor: Dr Abdurrahman Yurtaslan Ankara Oncology Training and Research Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Young adult leukemia study pulled before it began
Knowledge-focused TerminatedThis was a planned French study to collect information on chronic myeloid leukemia (CML) in young adults aged 18 to 30 who were treated with tyrosine kinase inhibitors. The goal was to describe their diagnosis, treatment choices, side effects, and quality of life. However, the st…
Sponsor: Centre Hospitalier Universitaire de Nice • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
New study tracks cancer patients at home to improve care
Knowledge-focused OngoingThis study looks at a program where cancer patients report their symptoms from home using a computer or phone. A navigator helps manage those symptoms. The goal is to see if this approach improves patient care and reduces emergency visits. About 3,090 adults with cancer are takin…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 14:00 UTC
-
Logbook study for stem cell patients pulled before start
Knowledge-focused TerminatedThis pilot study aimed to see if giving a logbook to patients hospitalized for a stem cell transplant could help reduce feelings of isolation and psychological stress. The study was withdrawn before enrolling any participants, so no results are available. It was planned at the Un…
Phase: NA • Sponsor: Centre Hospitalier Universitaire, Amiens • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:07 UTC
-
Blood cancer chemo and adrenal risk study pulled before start
Knowledge-focused TerminatedThis study planned to check how often the adrenal glands stop working properly after chemotherapy in adults with blood cancers. It aimed to measure cortisol levels after a stimulation test. However, the study was withdrawn before any participants were enrolled, so no results are …
Phase: NA • Sponsor: Rennes University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Keytruda immune response trial aims to unlock cancer clues
Knowledge-focused OngoingThis phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:05 UTC
-
Cancer patients get help planning families in new study
Knowledge-focused OngoingThis study tested a program to help cancer patients understand their fertility risks and get the right care. It included 434 women aged 15-55 with a new cancer diagnosis. The program aimed to connect them with specialists for pregnancy planning or fertility preservation based on …
Phase: NA • Sponsor: ECOG-ACRIN Cancer Research Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Scientists hunt for genetic clues in blood and urine to personalize lung cancer care
Knowledge-focused OngoingThis study collects blood, urine, and tissue samples from 330 adults with advanced lung or head and neck cancer to improve precision medicine. Researchers will analyze genetic changes in these samples and grow some tumors in mice to compare DNA. The goal is to refine liquid biops…
Phase: NA • Sponsor: University of Arkansas • Aim: Knowledge-focused
Last updated Jun 27, 2026 13:00 UTC
-
Cancer patients' family talks about genetic surprises studied
Knowledge-focused OngoingThis study explores how cancer patients feel and what they do when they learn about extra genetic findings from their tumor tests. Researchers want to understand how patients decide to share this information with their family members. About 495 adults with solid tumors are taking…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:37 UTC
-
Microdose cancer drug test could reveal best treatments without side effects
Knowledge-focused OngoingThis early-phase study tests very small amounts of cancer drugs injected directly into accessible tumors in 15 adults scheduled for surgery. The goal is to see how the drugs affect the tumor's environment, like killing cancer cells or activating immune cells, without causing full…
Phase: EARLY_PHASE1 • Sponsor: Presage Biosciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Fitness check may guide better leukemia care for seniors
Knowledge-focused OngoingThis study looks back at medical records of 725 older adults (over 65) with acute myeloid leukemia (AML). Researchers want to see if using a special 'fitness' score to choose treatment leads to longer survival. No new treatments are given; the goal is to learn which treatment app…
Sponsor: Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:36 UTC
-
Cancer imaging study pulled before starting
Knowledge-focused TerminatedThis study aimed to test a new device that rotates patients horizontally to take CT images for guiding radiation therapy in cancer patients. It was designed for adults with certain cancers, but the trial was withdrawn before enrolling anyone. The goal was to see if the images wer…
Phase: EARLY_PHASE1 • Sponsor: University of Sydney • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:35 UTC
-
Cannabis withdrawal in cancer patients: a hidden struggle during transplant?
Knowledge-focused ENROLLING_BY_INVITATIONThis study aims to find out how often cannabis withdrawal happens and how severe it is in patients with blood cancers who are hospitalized for a bone marrow transplant or CAR-T therapy. Researchers will track symptoms like mood changes and physical discomfort using a standard que…
Sponsor: Mayo Clinic • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
Leukemia relapse predictor study pulled before starting
Knowledge-focused TerminatedThis study aimed to see if tracking a specific gene mutation (c-Kit) could help predict relapse in acute myeloid leukemia patients. It planned to compare this method with current monitoring techniques. However, the study was withdrawn before enrolling any participants, so no resu…
Sponsor: Institute of Hematology & Blood Diseases Hospital, China • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:34 UTC
-
One workout could boost cancer fighters?
Knowledge-focused OngoingThis study compares how a single bout of exercise changes immune cells and inflammation in cancer patients undergoing chemotherapy and in healthy people of the same age. Researchers will measure natural killer cells and other immune markers before and after exercise. The goal is …
Phase: PHASE2 • Sponsor: Universität Duisburg-Essen • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:32 UTC
-
Leukemia study questions need for immediate second chemo after bone marrow test
Knowledge-focused OngoingThis study looks at whether it is safe to wait before giving a second round of chemotherapy to adults newly diagnosed with acute myeloid leukemia (AML), even if a mid-treatment bone marrow biopsy shows some remaining disease. About 60 participants will receive standard first chem…
Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
New app helps cancer patients get housing and food support
Knowledge-focused OngoingThis study tests a digital platform called ConnectedNest that helps cancer patients find and connect with social services like housing assistance, food aid, and financial help. About 400 adults with cancer in Minnesota will use the platform for 90 days. Researchers will measure i…
Phase: PHASE2 • Sponsor: University of Minnesota • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Massive 75,000-Patient registry aims to unlock best uses of proton therapy
Knowledge-focused ENROLLING_BY_INVITATIONThis registry follows up to 75,000 cancer patients treated with proton or standard X-ray radiation at Loma Linda University Medical Center, some since 1990. The goal is to track long-term outcomes like disease-free survival and local recurrence to learn which radiation approaches…
Sponsor: Loma Linda University • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Patients claim cannabis stops tumor growth – scientists investigate
Knowledge-focused OngoingThis study looks at medical records of 50 cancer patients who say cannabis helped stop their tumor from growing or shrank it. Researchers want to see if there is real evidence behind these claims. The goal is to gather information, not to test a new treatment.
Sponsor: HealthPartners Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:30 UTC
-
Can a statin tame a cancer protein? early trial seeks answers
Knowledge-focused OngoingThis early-stage study tests whether the cholesterol drug atorvastatin can reduce levels of a faulty protein (p53) in people with various cancers, including solid tumors and leukemia. About 50 participants will take atorvastatin for 1 to 4 weeks before their planned surgery or tr…
Phase: PHASE1 • Sponsor: Joaquina Baranda • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:29 UTC
-
Brain scan breakthrough could spot MS cognitive decline early
Knowledge-focused ENROLLING_BY_INVITATIONThis study is testing whether a new type of MRI can detect changes in the brain that lead to memory and thinking problems in people with multiple sclerosis (MS). Researchers will scan 75 adults with MS and give them thinking and memory tests. The goal is to see if the new MRI mea…
Sponsor: University of Wisconsin, Madison • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:25 UTC
-
Can new outreach methods boost minority enrollment in cancer trials?
Knowledge-focused OngoingThis study looks at different ways to reach out to African American patients and their doctors to see if it helps more of them join early phase cancer treatment trials. About 134 people will take part. The goal is to find better methods to make cancer research more inclusive.
Phase: NA • Sponsor: University of Chicago • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Can tumor profiling help kids beat cancer? new study aims to find out
Knowledge-focused OngoingThis study looks at whether testing the genes of a child's solid tumor can help doctors choose a more effective treatment. About 825 children and young adults with hard-to-treat solid tumors will have their tumors genetically profiled. The goal is to see if those who receive a tr…
Sponsor: Dana-Farber Cancer Institute • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:24 UTC
-
Smartwatches track cancer symptoms at home
Knowledge-focused ENROLLING_BY_INVITATIONThis study explores whether wearable devices, like smartwatches, can help monitor symptoms in cancer survivors. Twenty participants will wear a sensor-packed device that tracks temperature, heart rate, sleep, and activity. Researchers will see how many people agree to use the wea…
Phase: NA • Sponsor: University of Alabama at Birmingham • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Pregnancy DNA test may spot cancer in Moms-to-Be
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at whether the standard blood test given to pregnant women to screen for fetal conditions can also detect signs of cancer in the mother. Researchers will analyze DNA from 300 pregnant women with known or newly diagnosed cancer to identify specific chromosomal pat…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:23 UTC
-
Simple senior health quiz may predict chemo dangers
Knowledge-focused OngoingThis study looks at whether a special health assessment for older adults with cancer can help doctors predict and reduce serious side effects from chemotherapy. About 600 patients with solid tumors will be evaluated before starting treatment. The goal is to improve care and quali…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Can tablets replace paper for senior cancer patients?
Knowledge-focused OngoingThis study looks at whether older adults with cancer can use computer surveys (like on a tablet or computer) to answer health questions. Researchers want to see if these digital tools are easy to use, reliable, and give the same results as paper surveys. About 100 people aged 65 …
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Massive study of 190,000 workers to uncover hidden radiation risks
Knowledge-focused OngoingThis study follows about 190,000 Korean radiation workers to see if low-dose radiation exposure over time increases the risk of cancer and other diseases. Researchers will link national health records to track health outcomes. The goal is to better understand the long-term effect…
Sponsor: Korea Institute of Radiological & Medical Sciences • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:09 UTC
-
Could your phone camera replace blood tests? new study explores
Knowledge-focused OngoingThis study follows 60 people with lower-risk myelodysplastic neoplasms (MDS) who need regular red blood cell transfusions. Over 6 months, participants use a smartphone app to answer weekly quality-of-life questions and take photos of their fingernails or eyelids. Researchers aim …
Sponsor: University of Leipzig • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:08 UTC
-
New study observes patients getting nasal stem cell therapy for brain conditions
Knowledge-focused ENROLLING_BY_INVITATIONThis observational study follows 36 people with neurologic conditions like traumatic brain injury, cerebral palsy, multiple sclerosis, or Alzheimer's who are already receiving intranasal MuSE stem cell or exosome therapy as part of their routine care. Researchers track safety and…
Sponsor: Healing Hope International • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:05 UTC
-
New study aims to better detect depression in older adults with cancer
Knowledge-focused OngoingThis study aims to create a more accurate way to measure depression in older adults who have or had cancer. Researchers will interview patients and test a new questionnaire designed specifically for this group. The goal is to improve how doctors identify and treat depression in o…
Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
Tracking childhood cancer survivors for decades to improve their future health
Knowledge-focused OngoingThis long-term study follows 5,000 childhood cancer survivors who had a stem cell transplant or treatment for leukemia or solid tumors. Researchers collect health updates and quality-of-life questionnaires over 20+ years to understand late effects of therapy. The goal is to reduc…
Sponsor: Children's Oncology Group • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:04 UTC
-
New tool aims to predict chemo risks for seniors
Knowledge-focused OngoingThis study tests whether a geriatric assessment tool—looking at thinking, memory, daily activities, and emotional well-being—can predict serious side effects from chemotherapy in older adults with cancer. Over 1,000 patients completed questionnaires and cognitive tests before and…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
New study aims to improve cancer pain management
Knowledge-focused OngoingThis study looks at how people with chronic cancer pain take their long-acting opioid medications. The goal is to learn from their experiences and develop a better way to manage cancer pain. About 150 adults who are prescribed long-acting opioids for cancer pain will participate.…
Phase: NA • Sponsor: Massachusetts General Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 12:01 UTC
-
Skin sensor could alert doctors to rising pain in cancer and COPD patients
Knowledge-focused OngoingThis study tests whether a wearable skin sensor can tell the difference between mild, moderate, and severe pain in 37 adults with cancer or COPD. Participants wear the device for up to a week and report their pain levels. The goal is to create an algorithm that alerts caregivers …
Sponsor: Copenhagen University Hospital, Hvidovre • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:03 UTC
-
New blood test could spot cancer return after transplant
Knowledge-focused OngoingThis study is testing a new blood test called AlloHeme that measures how much of a patient's own cells remain after a bone marrow transplant. The goal is to see if this test can predict whether the cancer (acute leukemia or myelodysplastic syndrome) will come back. About 307 adul…
Sponsor: CareDx • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Study probes Patients' minds, not their tumors
Knowledge-focused OngoingThis study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…
Sponsor: Tomas Bata Hospital, Czech Republic • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
CAR-T therapy patients monitored for years in new safety study
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows 178 patients who previously received an AvenCell CAR-T cell therapy for cancers like lymphoma, leukemia, or prostate cancer. Researchers will track delayed side effects, including new cancers or autoimmune issues, for years. No new treatment is given—this is pu…
Sponsor: AvenCell Therapeutics, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:02 UTC
-
Lab test could match cancer patients to the right drugs
Knowledge-focused OngoingThis study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…
Sponsor: China Medical University Hospital • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Racial gap in cancer treatment? new study investigates immunotherapy outcomes
Knowledge-focused OngoingThis study is collecting blood, saliva, and health information from 2,100 Black and White cancer patients who are receiving immunotherapy (drugs that help the immune system fight cancer). The goal is to see if there are differences in side effects and how well the treatment works…
Sponsor: University of Rochester NCORP Research Base • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New study aims to predict and prevent dangerous drug reactions
Knowledge-focused OngoingThis study looks at whether combining genetic tests, regular drug level checks, and careful medication reviews can help doctors prescribe the right drugs and avoid harmful side effects. It involves 450 adults with cancer and children with chronic inflammatory diseases. The goal i…
Sponsor: Direzione centrale salute, politiche sociali e disabilità • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
15-Year safety check for caribou cell therapy patients
Knowledge-focused ENROLLING_BY_INVITATIONThis study follows about 150 people who previously received Caribou cell therapy for blood cancers like lymphoma or leukemia. Researchers will check for long-term side effects and overall survival for up to 15 years after treatment. No new treatment is given—this is just observat…
Sponsor: Caribou Biosciences, Inc. • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
Study on COVID-19 and blood cancer connection pulled before starting
Knowledge-focused TerminatedThis study was designed to learn how the protein calprotectin might change blood stem cells in people with severe COVID-19 or certain blood cancers. Researchers planned to compare cells from patients and healthy donors in the lab. However, the study was withdrawn before any parti…
Phase: NA • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:01 UTC
-
New approach aims to boost cancer trial awareness and participation
Knowledge-focused OngoingThis study tests a communication method to help cancer patients and the general public learn about clinical trials and make informed decisions about joining. About 581 participants will receive information to increase their awareness and positive attitudes toward trials. The goal…
Phase: NA • Sponsor: The University of Texas Health Science Center at San Antonio • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
Real-Time proton beam tracking could sharpen cancer therapy
Knowledge-focused OngoingThis study tests a new way to monitor proton therapy for solid tumors. A full-digital PET scanner tracks the proton beam's path and dose in real time. Thirty patients scheduled for proton therapy will participate. The goal is to improve treatment accuracy by seeing exactly where …
Sponsor: Shuanghu Yuan • Aim: Knowledge-focused
Last updated Jun 27, 2026 11:00 UTC
-
New MRI-Guided radiotherapy machine put to the test
Knowledge-focused OngoingThis study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.
Phase: NA • Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Can a team of experts help older cancer patients bounce back after transplant?
Knowledge-focused OngoingThis study tests whether a program where older adults (65+) with blood cancer see a team of healthcare providers can help them stay fit and resilient after a stem cell transplant. The program includes health coaching, quality-of-life assessments, and questionnaires. The main goal…
Phase: NA • Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:11 UTC
-
Scientists probe how a natural substance fuels leukemia
Knowledge-focused OngoingThis study examines how adrenomedullin, a natural protein, affects leukemia stem cells in patients with acute myeloid leukemia (AML). Researchers will collect bone marrow and blood samples from 72 newly diagnosed AML patients to measure adrenomedullin levels and study its effects…
Phase: NA • Sponsor: Gruppo Italiano Malattie EMatologiche dell'Adulto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
MRI-Guided radiation: a sharper weapon against cancer?
Knowledge-focused OngoingThis study is testing a new radiation technique that uses real-time MRI scans to target cancer more precisely. About 377 adult cancer patients will receive this treatment and have extra scans and quality-of-life surveys. The goal is to see if this approach improves tumor control …
Sponsor: University Health Network, Toronto • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Gut check: Antibiotics' hidden impact on transplant recovery
Knowledge-focused OngoingThis study looks at how different antibiotics change the friendly bacteria in the gut of people who have had a stem cell transplant and develop a fever with low white blood cells. The goal is to understand which antibiotics are gentler on these helpful bacteria, which may lead to…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can a lab test predict which chemo works best? new study aims to find out
Knowledge-focused OngoingThis study looks at whether testing cancer cells in a lab can predict how well chemotherapy will work for people with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS). Researchers will take blood and bone marrow samples before and during treatment to see if lab res…
Sponsor: Washington University School of Medicine • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:10 UTC
-
Can we track brain health in older cancer patients?
Knowledge-focused OngoingThis study looks at whether it's possible to track memory and thinking changes in adults aged 65 and older who are starting a new type of cancer treatment called immune checkpoint inhibitors. Thirty participants will take simple memory and concentration tests every six weeks for …
Sponsor: Our Lady's Hospice and Care Services • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:09 UTC
-
Why do cancer patients fear painkillers? new study investigates
Knowledge-focused OngoingThis study looks at why some adults with advanced cancer are afraid to take opioids for pain, even when prescribed. Researchers will survey 50 patients to measure how fear, anxiety, and depression affect pain levels and medication use. The goal is to identify barriers so that pai…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:06 UTC
-
Cancer Patients' pandemic struggles revealed in new study
Knowledge-focused OngoingThis study surveys over 1,200 cancer patients who previously took part in behavioral trials to learn how the COVID-19 pandemic impacted their quality of life, mental health, and daily routines. Participants fill out questionnaires about stress, sleep, diet, exercise, and social s…
Sponsor: M.D. Anderson Cancer Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:05 UTC
-
7,000 tumor samples analyzed to uncover Cancer's hidden support system
Knowledge-focused OngoingThis study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …
Sponsor: University Hospital, Brest • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:04 UTC
-
Scientists hunt for genetic clues in childhood leukemia
Knowledge-focused OngoingThis study looks at genetic changes in cancer stem cells from children and young adults with acute leukemia. Researchers will analyze bone marrow or blood samples to find gene patterns that may drive the disease. The goal is to better understand leukemia and potentially discover …
Sponsor: Sanford Health • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
New study examines immunotherapy outcomes in american indian cancer patients
Knowledge-focused OngoingThis study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…
Sponsor: University of Oklahoma • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:03 UTC
-
Telehealth under the microscope: did virtual cancer care hold up during COVID?
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how doctors and nurses in radiation oncology used telehealth instead of in-person visits during the COVID-19 pandemic. Researchers will survey 1,000 healthcare providers at Duke Cancer Center to understand their experiences and challenges. They will also track…
Sponsor: Duke University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:02 UTC
-
Jaw pain mystery: scientists probe genes and feelings for clues
Knowledge-focused ENROLLING_BY_INVITATIONThis study looks at how chronic jaw muscle pain relates to genetics, blood chemicals, and emotional state. Researchers will compare 102 adults with and without jaw pain to find connections. No treatment is given; the goal is to better understand the condition.
Sponsor: Wroclaw Medical University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Can a short video help cancer patients get better palliative care?
Knowledge-focused OngoingThis study tests whether an educational video can help adults with serious cancer understand and use palliative care. 172 participants will either receive standard care plus brochures, or standard care plus a tailored video and extra materials. Researchers will track knowledge, a…
Phase: NA • Sponsor: Tulane University • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:01 UTC
-
Italy launches massive genetic database to match cancer patients with better treatments
Knowledge-focused OngoingThis observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…
Sponsor: Federation of Italian Cooperative Oncology Groups • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Light therapy under the microscope: can it soothe mouth sores after transplant?
Knowledge-focused OngoingThis study looks at how photobiomodulation (a type of light therapy) affects mouth sores and other oral symptoms in patients receiving a stem cell transplant. Researchers will track pain, taste changes, and dry mouth in about 6 patients. The goal is to gather information to impro…
Sponsor: City of Hope Medical Center • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:00 UTC
-
Expert panel boosts precision cancer care in new study
Knowledge-focused OngoingThis study looks at whether a special team of doctors and scientists (a genomic tumor board) can help more patients with advanced solid tumors get treatments that match their cancer's genetic makeup. About 1,284 patients will take part. The goal is to see if this team approach le…
Phase: NA • Sponsor: SWOG Cancer Research Network • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:13 UTC